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Abbreviations 
A2A-AdoR A2A-adenosine receptor 
AC adenylyl cyclase 
ACh acetylcholine (agonist for muscarinic acetylcholine receptors) 
AKAP A-kinase anchoring protein 
ATP adenosine triphosphate 
α2A-AR α2A-adrenoceptor 
β-AR β-adrenoceptor (type 1 or 2) 
cAMP cyclic adenosine monophosphate 
Cer Cerulean (a variant of eCFP) 
CFP cyan fluorescent protein (eCFP: enhanced CFP) 
CHO chinese hamster ovary (cell line) 
DMEM Dulbecco’s Modified Eagle’s Medium 
EC50 half-maximal effective concentration (concentration-response curves) 
Epac exchange protein directly activated by cAMP 
Epac1-camps FRET-based cAMP sensor, which contains the Epac1-domain 
FCS fetal calf serum 
FRAP Fluorescence Recovery After Photobleaching 
FRET Förster/Fluorescence Resonance Energy Transfer 
FSK forskolin 
GFP green fluorescent protein 
GIRK channel G-protein-gated inwardly rectifying K
+
 channel 
GPCR G-protein-coupled receptor 
G-protein guanine nucleotide binding protein (s: stimulatory; i: inhibitory) 
Gαi/AC5-FRET FRET-assay, the labelled proteins are Gαi1-CFP and YFP-AC5 
Gαi/Gβγ-FRET FRET-assay, the labelled proteins are Gαi1-YFP and CFP-Gγ2 
HEK human endothelial kidney (cell line; used in this study: HEK293T) 
HRP horse radish peroxidase 
Iso isoprenaline (agonist for β-AR) 
kDa kilo Dalton 
M2-AChR type 2 muscarinic acetylcholine receptor (also other types) 
NE norepinephrine (agonist for α2A-AR and β-AR) 
PAGE polyacrylamide gel electrophoresis 
vii 
 
PBS phosphate buffered sodium (buffer) 
PCR polymerase chain reaction 
PDE phosphodiesterase 
PKA protein kinase A 
PLC phospholipase C 
RGS4 regulator of G-protein signalling type 4 
S.E.M. standard error of the mean 
SDS Na
+
 dodecyl sulphate 
t0.5 time to half-maximal stimulation or recovery (in FRET recordings) 
wt wild-type 
YFP yellow fluorescent protein 
[cAMP] cAMP concentration (also used with other substances) 
 
About G-proteins: 
In the following sections G-protein names without index, e.g. Gs-protein or Gi1-protein, 
are used for the respective heterotrimeric G-proteins. Indices are used for specific 
subunits, e.g. Gαs or Gαi1. If the text refers to “Gβγ-subunit”, this means the 
combination of Gβ1 and Gγ2. No other combination of Gβ- and Gγ-subunits was 
investigated during this study. 
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1 Introduction 
The signalling pathway from G-protein-coupled receptors (GPCRs) to the regulation of 
cytosolic levels of cAMP (cyclic adenosine monophosphate) is present in virtually all 
cells. These receptors, being membrane spanning proteins, are the largest family of drug 
targets. Many drugs, including important classes like “β-blockers” (β1-adrenergic 
antagonists, e.g. metoprolol) and blockbusters such as β2-sympathomimetics (e.g. 
salmeterol), exert their pharmacological effect through the regulation of cellular cAMP 
levels. This second messenger mediates many important physiological functions like 
heart frequency, contraction and ultimately blood pressure, relaxation of smooth muscle 
cells or insulin secretion (Metrich et al., Pflugers Arch. 2010; Halls and Cooper, Cold 
Spring Harb. Perspect. Biol. 2011). β1-adrenergic antagonists lower cAMP and thereby 
reduce heart rate, cardiac output and finally the blood pressure. β2-adrenergic agonists 
are used to relieve patients suffering from asthmatic attacks, because they increase 
cellular cAMP which relaxes smooth muscle cells and thereby increases the diameter of 
the bronchi. 
Cellular levels of cAMP are carefully regulated by three main mechanisms: 
A) stimulation or B) inhibition of the production and C) degradation (see Figure 1).  
A) Stimulation of the production is the result of the activation of GPCRs that couple to 
stimulatory G-proteins (Gs-proteins, guanine nucleotide-binding proteins) (Northup et 
al., Proc. Natl. Acad. Sci. U. S. A. 1980), which in turn increases the enzymatic activity 
of adenylyl cyclases (ACs). ACs are the family of enzymes, that actually catalyse the 
conversion of ATP (adenosine triphosphate) into cAMP. β2-adrenergic agonists are 
important examples for this stimulation of AC activity and the increase in cellular 
cAMP levels. β1-adrenergic antagonists prevent the activation of the stimulatory 
pathway, which ultimately lowers cellular cAMP levels. B) Cellular levels of cAMP can 
also be lowered through the direct activation of inhibitory G-proteins (Gi-proteins) 
(Bokoch et al., J. Biol. Chem. 1983). These inhibit cAMP production and the cAMP-
degrading members of the PDE-superfamily (phosphodiesterases) (Essayan, J. Allergy 
Clin. Immunol. 2001) will further decrease the second messenger levels. The activation 
of Gi-coupled receptors is the cellular mode of action of morphine, a very potent 
analgesic. C) Interference with cAMP degradation by PDEs can further regulate cellular 
cAMP concentration. Theophylline, used against asthma as the β2-adrenergic agonists, 
elevates cAMP by inhibiting the degradation through PDEs.  
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Figure 1: Stimulatory and inhibitory signalling from GPCRs via G-proteins and ACs to 
the second messenger cAMP 
GPCRs activate their respective G-proteins, which will subsequently stimulate or inhibit ACs. 
This regulates the generation of the second messenger cAMP. cAMP can elicit several 
functions, some of them depicted in this scheme. Degradation of cAMP by PDEs will influence 
the cellular amount of cAMP and the according signalling pathways. Further details are 
provided in the text. Please note, that the AC is displayed with its N-terminus to the right to 
allow for better schematic display of the interaction with G-protein subunits. 
According to the abundance of the above signalling cascade, detailed knowledge about 
the interaction between the partners involved is essential for the understanding of 
cellular processes as well as the generation and optimisation of therapeutic drugs. 
Biochemical research has provided detailed knowledge about the interaction between 
G-proteins and ACs (Sunahara et al., Annu. Rev. Pharmacol. Toxicol. 1996; Tesmer and 
Sprang, Curr. Opin. Struct. Biol. 1998). In addition, the development of new 
microscopic methods revealed many of the dynamics of the signalling pathway (see 
(Lohse et al., Trends Pharmacol. Sci. 2008) and (Lohse et al., Pharmacol. Rev. 2012) 
for recent reviews). However, some questions remained open, especially concerning the 
dynamics of AC regulation. 
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In the following, the individual partners of this signalling cascade will be introduced 
separately from the receptor via the G-proteins to ACs and finally the second messenger 
cAMP. 
1.1 G-protein-coupled receptors (GPCRs) 
Most prominently, GPCRs consist of seven membrane-spanning helices and are also 
referred to as 7TM-receptors (7 transmembrane), accordingly. 
While most of the receptors will bind their ligands in a binding pocket inside the 
TM-bundle, some receptors also have ligand binding domains on their N-termini 
(Baldwin, Curr. Opin. Cell Biol. 1994; Fredriksson et al., Mol. Pharmacol. 2003). 
These receptors will usually bind peptides like the luteinising hormone (LH) or thyroid-
stimulating hormone (TSH). 
In the past few years, much insight was gained into the structure of GPCRs. Rhodopsin, 
the light-receptor of the visual system, had been crystallised about 13 years ago 
(Palczewski et al., Science 2000), but it took until 2007 to crystallise another human 
receptor, the β2-adrenoceptor (Rasmussen et al., Nature 2007). 
The third intracellular loop together with the C-terminus is a major interaction site for 
heterotrimeric G-proteins (Holthoff et al., Circ. Res. 2012). Upon ligand binding to the 
receptor several helices will undergo conformational changes. The most prominent 
change is the opening of a cleft on the intracellular side of the receptor through 
rearrangement of the helices 5 and 6 (Deupi and Standfuss, Curr. Opin. Struct. Biol. 
2011). This cleft provides the binding moiety for the C-terminus of the G-protein 
α-subunit (Rasmussen et al., Nature 2011). 
Although there are about 700 genes for GPCRs of the Rhodopsin family (Fredriksson et 
al., Mol. Pharmacol. 2003), there are only four major classes of G-proteins the receptors 
will interact with. They can therefore be divided into Gs-, Gi/o-, Gq/11- and 
G12/13-coupled receptors. According to the G-protein family it couples to, each 
receptor will stimulate distinct pathways. 
There are some other types of GPCR-signalling apart from the activation of G-proteins. 
These pathways are referred to as non-canonical and include the activation of and 
signalling via GRKs (G-protein-coupled receptor kinase), arrestins and other molecules, 
such as RhoA, MAP kinase and NF-κB (Zhang and Eggert, Mol. Biosyst. 2013). These 
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signalling events do not elicit the interaction between G-proteins and ACs and therefore 
have not been investigated in this study. 
1.1.1 β2-adrenoceptor 
In these studies the pharmacological relevant β2-adrenoceptor (β2-AR) was used as a 
model receptor to activate stimulatory G-proteins (Gs-proteins). This receptor is 
endogenously expressed in many cell types and tissues (Uhlen et al., Nat. Biotechnol. 
2010), including the HEK293T cell line used in this study. This enabled stimulation of 
the Gs-signalling pathway without additional transfection of the receptor, which was 
important for some functional experiments. 
Closely related to the β2-AR is the β1-AR, which is mainly expressed in the heart. The 
β2-AR is also expressed in the heart, but it seems to be of less importance when it comes 
to the mediation of adrenergic response (Chruscinski et al., J. Biol. Chem. 1999). 
However, it is widely distributed throughout muscle tissues, especially smooth muscles 
in the uterus, gut, endothelium and bronchi. Agonists of the β2-AR are, for example, 
used in the treatment of asthma and COPD (chronic obstructive pulmonary disease), 
where they relax the bronchi and thereby increase airway-diameter. Activation of 
β2-ARs in blood vessels has hypotensive effects, because the vessel diameter is 
increased. However, this principle is currently not used in therapy of hypertension, at 
least not on its own. Due to its expression in the uterus, β2-AR agonists can also be used 
to prevent labour and have been tested for treating dysmenorrhoea. However, the drugs 
also activate the β1-AR and adverse effects limit their safety and use (Fedorowicz et al., 
Cochrane Database Syst. Rev. 2012). To prevent adverse cardiac effects like 
tachycardia, β2-AR agonists are designed to preferentially activate β2-AR over β1-AR. 
Another option to reduce adverse effects is to apply the substances locally. In the eye, 
β2-ARs control the production of the intraocular fluid and local application of β2-AR 
antagonists is used to treat glaucoma, mainly by inhibiting new liquid production. The 
endogenous ligands for this receptor are epinephrine and with less potency 
norepinephrine (NE) (Sharman et al., Nucleic Acids Res.). The pharmacological tool 
compound isoprenaline (Iso) is structurally closely related to epinephrine and equally 
potent. In the present study Iso was used to selectively stimulate β2-adrenoceptors. 
The β2-AR has been shown to dimerise (Hebert et al., J. Biol. Chem. 1996; Dorsch et 
al., Nat. Methods 2009). Receptor-dimerisation is a model with steady growing 
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evidence (see (Milligan, Mol. Pharmacol. 2013) for a recent review). Homodimerisation 
of the β2-AR has been shown to be necessary for proper membrane targeting (Salahpour 
et al., J. Biol. Chem. 2004) as well as receptor activation and signalling (Hebert et al., J. 
Biol. Chem. 1996). However, the functional relevance of GPCR-dimers remains 
unsolved. 
1.1.2 α2A-adrenoceptor 
The α2A-adrenoceptor (α2A-AR) was used to activate the inhibitory G-proteins 
(Gi-proteins) in this study. The α2A-AR is predominately expressed in the brain where it 
is involved in synaptic function. It controls the release of neurotransmitters, especially 
by a negative feedback mechanism (Hein et al., Nature 1999). Pharmacological 
activation of this receptor, e.g. by clonidine, is used to treat hypertension. Clonidine 
activates the α2A-AR and thereby reduces catecholamine-release, which results in 
decreased blood pressure and cardiac activity. In addition clonidine binds to imidazoline 
receptors of the medulla oblongata, which adds to the hypotensive effect (Bousquet et 
al., J. Pharmacol. Exp. Ther. 1984). Because of the presence of the α2A-AR in the 
central nervous system it seems to be related to further CNS effects. Clonidine is 
discussed to be effective in addition to morphine treatment (Engelman and Marsala, Br. 
J. Anaesth. 2013) and attention-deficit/hyperactivity disorder (Childress and Sallee, 
Drugs Today (Barc) 2012). 
Like other adrenoceptors, the α2A-AR is endogenously activated by epinephrine and 
norepinephrine. The latter was used to activate the signalling pathway. Upon activation 
of the receptor and subsequently the Gi-protein, ACs will be inhibited and cellular 
cAMP levels will be decreased. This effect is mainly mediated by the Gαi-subunit. 
Gβγ-subunits derived from Gi-proteins can directly activate G-protein-gated inwardly 
rectifying K
+
 channels (GIRK channel) as well as inhibit N-type Ca
2+
 channels. The 
latter is an important mediator of the presynaptic inhibition of neurotransmitter release 
(Currie, Channels (Austin) 2010). 
The α2A-AR has recently been shown to be voltage-dependent in the presence of agonist 
(Rinne et al., Proc. Natl. Acad. Sci. U. S. A. 2013). Physiological membrane potentials 
promote the activation of the receptor, whereas depolarisation deactivates the receptor, 
obviously by reducing ligand binding. As the receptor is localised in neurons and will 
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therefore be exposed to changes in the membrane potential quite frequently, the voltage 
sensitivity might provide a potent and fast regulation mechanism for this receptor. 
1.2 G-proteins 
G-proteins were initially identified, because the researchers were trying to identify the 
regulatory subunit of adenylyl cyclases (Northup et al., Proc. Natl. Acad. Sci. U. S. A. 
1980). Their name is derived and abbreviated from their ability to bind guanine 
nucleotides. G-proteins are heterotrimeric proteins, consisting of α-, β- and γ-subunits. 
β- and γ-subunits have a very high affinity towards each other and do not dissociate 
under normal conditions. As they act as a heterodimer, they will be referred to as Gβγ in 
the following. Currently 23 α-, 5 β- and 12 γ-subunits are known (McCudden et al., 
Cell. Mol. Life Sci. 2005). The α-subunit contains the binding site for the nucleotide. It 
is also the subunit that defines the G-protein’s state of activity. If GDP is bound, the 
G-protein is inactive, while the GTP-bound protein is active. Please refer to section 
1.2.4 for a more detailed description of the G-protein cycle. There is also an 
intermediate state, where no nucleotide is bound to the α-subunit. This state is 
considered a high-affinity state for the interaction with an active GPCR. 
According to common theory, the heterotrimeric G-protein will dissociate upon 
activation and the Gα- and Gβγ-subunits will interact with their individual effectors. 
This model might not properly reflect the endogenous situation in all G-protein types, 
though. Resonance energy transfer (RET)-based assays resolve protein/protein 
interactions and are used to investigate agonist-mediated G-protein activation. These 
assays should report a loss of RET upon protein dissociation. At least the Gi-protein is 
unlikely to fully dissociate, as the RET-signal increases under certain conditions (see 
section 1.5.1 for further details). This suggests subunit rearrangement rather than 
dissociation, at least in the absence of effector proteins. 
1.2.1 Gα-subunits 
As mentioned above, the G-proteins can be divided into four major classes (Gs, Gi/o, 
Gq/11 and G12/13), defined by their α-subunits. Their N-terminus is posttranslationally 
either myristinylated or palmitoylated to ensure membrane association (McCudden et 
al., Cell. Mol. Life Sci. 2005). Of the four, only Gαs and Gαi interact with adenylyl 
cyclases. Gαs-subunits activate all nine membrane integrated AC isoforms (Pavan et al., 
Drug Discov. Today 2009) and thereby stimulate the production of cAMP. Gαi-subunits 
will inhibit the production of cAMP, at least through the AC isoforms I, V and VI. 
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While Gαs is expressed abundantly, Gαi1 is mostly expressed in the brain. Gαi2 and Gαi3 
are important subunits in the immune system (Wiege et al., J. Immunol. 2013) and the 
heart (Hippe et al., Naunyn-Schmiedeberg's Arch. Pharmacol. 2013). Further details on 
the interaction with ACs and the subsequent effects of cAMP are introduced in sections 
1.3ff. 
The main effectors of Gq-proteins are phospholipases and their second messengers are 
DAG (diacyl-glycerol) and IP3 (inositol-trisphosphate) (Jensen et al., J. Gen. Physiol. 
2009). Accordingly Gαq was used for control purposes in this study. 
1.2.2 Gβγ-subunits 
Gβ- and Gγ-subunits form constitutively heterodimers and do not dissociate under 
normal conditions. Gγ is C-terminally prenylated and thereby provides the membrane 
anchor for the dimer. Most combinations of the 5 Gβ- and 12 Gγ-subunits are 
functional. Some combinations seem to preferentially bind certain receptors or activate 
specific signalling pathways (McCudden et al., Cell. Mol. Life Sci. 2005). However, 
there is currently no evidence showing the preference of individual Gβγ-combinations 
towards certain Gα-subunits. In this work, only Gβ1γ2-subunits were investigated. 
Like Gα, Gβγ-subunits can interact with effectors. Gi-derived Gβγ-subunits can interact 
with and stimulate the GIRK channel or inhibit N-type Ca
2+
 channels. 
Electrophysiological recording of the GIRK channel has classically been used to most 
directly monitor Gi-protein activity. ACs are also direct effectors of the Gβγ-subunits. 
AC isoforms II, IV and VII are activated by them, while type I AC is inhibited (Smrcka, 
Cell. Mol. Life Sci. 2008; Pavan et al., Drug Discov. Today 2009). There are conflicting 
reports on the regulation of type V AC (AC5) by Gβγ-subunits. While they have been 
stated to inhibit AC5 (Smrcka, Cell. Mol. Life Sci. 2008; Pavan et al., Drug Discov. 
Today 2009), they are also necessary for the activation of AC5 through Gαs (Gao et al., 
J. Biol. Chem. 2007) and have been shown to interfere with Gαi-mediated inhibition of 
AC5 (Sadana et al., Mol. Pharmacol. 2009). 
Most Gβγ-effectors are regulated by Gi-derived subunits – a quite elaborate list can be 
found in a review by Alan V. Smrcka (Cell. Mol. Life Sci. 2008). However, Gβγ and 
Gαs have been found to jointly interact with AC5 (Sadana et al., Mol. Pharmacol. 
2009). 
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1.2.3 Different sensitivity of Gαi- and Gi-derived Gβγ-pathways 
About 20 years ago an interesting effect of Gi-signalling was reported. AC5 is 
obviously very potently inhibited by Gi-proteins as observed by the specific regulation 
of it through D3 dopamine receptors (Robinson and Caron, Mol. Pharmacol. 1997). In 
addition, Li et al. discovered, that within the same cell type, there are several outcomes 
of the same receptor (J. Gen. Physiol. 1994). They reported that activation of type 2 
muscarinic acetylcholine receptor (M2-AChR) by low concentrations of agonist resulted 
in the inhibition of Ca
2+
 currents, while higher concentrations of ACh led to the 
activation of K
+
 currents. The inhibition of Ca
2+
 currents was a cAMP-dependent effect, 
while the activation of K
+
 currents was based on the G-protein activity-dependent 
activation of GIRK channels. These observations already hinted at a very specific 
interaction between Gi-proteins and ACs, especially AC5, a fact that also occurred in 
the course of this study. 
1.2.4 G-protein cycle and RGS proteins 
The G-proteins undergo an activation/deactivation-cycle as depicted in Figure 2. 
 
Figure 2: The G-protein cycle and the influence of RGS proteins 
G-proteins cycle through activation and deactivation. Binding of a ligand-activated receptor will 
lead to the exchange of GDP for GTP and thereby render the G-protein active and able to 
interact with its effector(s). The endogenous GTPase activity will cleave GTP to GDP again. 
The subunits will subsequently reassemble to their inactive conformation and the cycle will 
come to its closure. RGS proteins can accelerate the deactivation by enhancing the GTPase 
activity. 
In the G-protein’s inactive conformation GDP is bound to the α-subunit. The activated 
receptor will bind the inactive G-protein, which releases the bound GDP. The now 
nucleotide-free G-protein is stabilised by the active receptor before the α-subunit binds 
GTP and the G-protein is rendered active. This step occurs very fast, because of the 
high cellular concentration of GTP. The now active G-protein can interact with its 
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effectors. The deactivation of the G-protein is initiated when the endogenous GTPase 
activity of the Gα-subunit cleaves the bound GTP to GDP. Subsequently the G-protein 
subunits will establish their inactive conformation again. This deactivation step can be 
accelerated by so-called GAPs (GTPase activating proteins), e.g. the regulators of 
G-protein signalling (RGS proteins). Of the vast number of RGS proteins and proteins 
containing RGS-domains, the RGS4 family is the largest and has the least complicated 
domain structure. Members of this family basically consist of only the RGS domain and 
nearly all of them regulate Gi/o- and Gq-proteins (Kimple et al., Pharmacol. Rev. 
2011). RGS2 has been reported to reduce the activity of AC3 in olfactory neurons 
(Sinnarajah et al., Nature 2001), which hinted at regulation of Gs-proteins. Later work 
revealed that RGS2 directly binds to several AC isoforms (Salim et al., J. Biol. Chem. 
2003; Xie et al., Sci. Signal. 2012) and thereby directly reduces AC activity. Currently 
no RGS proteins are known that regulate Gs-protein and neither have Gs-protein GAPs 
been reported. When tested in vitro, RGS proteins increase the endogenous GTPase 
activity of the Gα-subunits (Watson et al., Nature 1996). This leads to an accelerated 
G-protein deactivation in vivo (Doupnik et al., Proc. Natl. Acad. Sci. U. S. A. 1997), 
which was identified by GIRK current measurements. In the current study, RGS4 was 
used in kinetic experiments to selectively accelerate Gi-protein deactivation and thereby 
alter kinetics of the G-protein cycle. 
Among the GTPase activating proteins, there are also G-protein effectors. PLC-β, for 
example, is an effector and GAP of the Gq-protein (Ross, Sci. Signal. 2011). So far no 
such functionality has been reported for ACs and this study also aimed to investigate 
potential G-protein regulation by this effector. 
1.3 Adenylyl cyclases 
The main function of adenylyl cyclases (ACs) is the production of the second 
messenger cAMP (cyclic adenosine-mono-phosphate) from ATP. Currently ten AC 
isoforms are known, nine of them being membrane-integrated. Type 10 AC is not a 
transmembrane protein and also referred to as soluble AC (sAC) (Gancedo, Biol. Rev. 
Camb. Philos. Soc. 2013). 
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Figure 3: Catalytic conversion of ATP to cAMP 
cAMP is generated from ATP by the cleavage of pyrophosphate and ring-closure between the 
oxygen of the ribose residue and the remaining phosphate. 
Biochemical research of the ACs revealed important structural information (for 
comparison see Figure 4). The mammalian membrane-integrated ACs consist of 12 
transmembrane helices, grouped into two bundles of six (Linder, Cell. Mol. Life Sci. 
2006). These two bundles are separated by a large intracellular loop, which is referred to 
as C1-domain, as it contains parts of the catalytic site. The C-terminus – after the 
second set of transmembrane helices – contains the second part of the catalytic domain 
and is therefore referred to as C2. Both catalytic domains are further subdivided into 
two parts (C1a and b; C2a and b). The N-terminus is implicated to be involved in self-
regulation of the AC, at least of AC5 (Sadana et al., Mol. Pharmacol. 2009). The whole 
enzyme is yet to be crystallised, but crystal structures exist for the catalytic domains. 
These were derived from a soluble chimeric heterodimer consisting of the C1-domain of 
AC5 and the C2-domain of AC2. The structures revealed the binding sites for the 
nucleotide (Tesmer et al., Science 1997), catalytically necessary cations like Mg
2+
 
(Tesmer et al., Science 1999), forskolin (Zhang et al., Nature 1997) and its analogues 
(Pinto et al., Biochem. Pharmacol. 2009). Furthermore, the interaction with Gαs was 
revealed (Tesmer et al., Science 1997) and the mode of inhibition of AC5 through Ca
2+
 
(Mou et al., Biochemistry (Mosc.) 2009). Biochemical approaches, including mutational 
studies, immunological and microscopic approaches, mapped the binding sites for 
different G-protein subunits (Sunahara et al., J. Biol. Chem. 1997; Dessauer et al., J. 
Biol. Chem. 1998; Wittpoth et al., Proc. Natl. Acad. Sci. U. S. A. 1999; Dessauer et al., 
J. Biol. Chem. 2002; Sadana et al., Mol. Pharmacol. 2009). 
 Introduction 
11 
 
1.3.1 Type 5 adenylyl cyclase 
Summarising the research mentioned above, the following is known about the activation 
of ACs in general and the regulation of AC5, specifically (refer to Figure 4 for a scheme 
of the individual domains). Forskolin and Gαs-GTP bind to the C2-domain. This 
enhances the affinity of C2 to C1 about 100-fold and activates ACs by facilitating the 
formation of the catalytic subunit (closed conformation of C1 and C2) and presumably 
further conformational changes. The nucleotide binds within this domain dimer, as well 
as the metal ion (Mg
2+
 in AC5), which establishes complex bonds to the pyrophosphate 
residue of the nucleotide (Tesmer and Sprang, Curr. Opin. Struct. Biol. 1998). Ca
2+
 
obviously competes with and displaces Mg
2+
, which results in the inhibition of AC5 and 
AC6, the most closely related isoform (Pavan et al., Drug Discov. Today 2009). Gαi1 
binds to the C1-domain opposite of Gαs-GTP on C2 and thereby interferes with catalytic 
core formation. The N-terminus of AC5 has several functions. It interacts with the 
C1-domain, thereby regulating Gαi-mediated inhibition of AC5 and also Gαs-mediated 
activation. The amino acids 60-129 have been mapped as the interaction site for 
Gβγ-subunits and Gαs-GDP. However, the actual transition from the inactive complex 
to the active conformation remains elusive. As the N-terminus is less conserved 
between AC5 and AC6, it might be the cause for regulatory differences between these 
otherwise closely related isoforms (Chen-Goodspeed et al., J. Biol. Chem. 2005). 
 
Figure 4: Domains of AC5 
AC5 consists of two bundles of each six transmembrane helices (blue). The N-terminus (red) 
contains binding sites for Gβγ and inactive Gαs. Gαi will bind within the C1-domain (yellow) 
and interfere with the formation of the catalytic core consisting of C1 and C2. The C2-domain is 
located on the C-terminus of AC5 (green) and also contains putative binding sites for active Gαs 
and forskolin. 
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AC5 mRNA is ubiquitously expressed (Wu et al., Genome Biol. 2009). AC5 is an 
important isoform in the heart, but hardly distinguishable from AC6 (Gottle et al., J. 
Pharmacol. Exp. Ther. 2009). Several physiological and pathophysiological functions 
have been linked to AC5, not least through the availability of AC5-knock-out mice. The 
central nervous system relies on AC5 in learning and memory (Kheirbek et al., J. 
Neurosci. 2009; Kheirbek et al., Learn. Mem. 2010). Furthermore, AC5 plays a relevant 
role in alcoholism (Kim et al., Psychopharmacology (Berl.) 2011) and further mediates 
morphine action (Kim et al., Proc. Natl. Acad. Sci. U. S. A. 2006). AC5 has also been 
identified as being involved in morphine withdrawal symptoms as it is hyperactivated 
after morphine treatment (Fan et al., Mol. Pharmacol. 2009). Deletion of AC5 protects 
the heart from cardiomyopathies (Yan et al., Cell 2007; Vatner et al., Circ. J. 2009), but 
overexpression is associated with hypertrophy. AC5-knock-out is also related to 
longevity, presumably through mechanisms closely related to metabolic changes in 
response to calorie restriction (Vatner et al., Aging (Albany NY) 2012). 
It is controversially discussed whether AC5-downregulation (potentially achieved 
through selective pharmacological inhibition) is generally beneficial. Although AC5 
and AC6 are closely related enzymes, their physiological function is distinct. 
Hypertrophy leads to an upregulation of AC5, while AC6 is downregulated and AC5-
overexpression seems to be predisposing for hypertrophy. This may be caused by the 
selective anchoring and subcellular localisation of AC5 by mAKAP (muscle protein 
A-kinase anchoring protein), a protein that does not bind AC6. Controversially to these 
observations, beneficial effects of AC5-overexpression have been found whenever 
cardiomyopathies have been associated to Gq-protein overexpression. These 
myopathies obviously result in a reduced expression of AC5, which explains why AC5-
overexpression could be beneficial (Vatner et al., Am. J. Physiol. Heart Circ.Physiol. 
2013). 
1.4 cyclic AMP (cAMP) 
cAMP was identified in 1957 as a “heat-stable factor (formed by particulate fractions of 
liver homogenates in the presence of ATP, Mg
++, and epinephrine or glucagon)” 
(Sutherland and Rall, J. Am. Chem. Soc. 1957). Soon it became evident that cAMP was 
present in virtually all cells and tissues (Sutherland and Robison, Pharmacol. Rev. 
1966). To establish the concept of cAMP being a second messenger, further regulatory 
mechanisms still had to be identified (Blumenthal, Perspect. Biol. Med. 2012). Today, a 
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wide variety of disease-treatment manipulates cellular levels of this second messenger 
(Pierre et al., Nat. Rev. Drug Discov. 2009). Meanwhile, cAMP effects have been 
identified in many organisms (Gancedo, Biol. Rev. Camb. Philos. Soc. 2013). 
Accordingly, it comes as no surprise, that even some bacterial toxins exert their effects 
via the alteration of cAMP, e.g. the edema factor of B. anthraxis, which elevates cAMP 
through its own adenylyl cyclase activity (Tang and Guo, Mol. Aspects Med. 2009). 
Cellular amounts of cAMP are controlled through its generation by adenylyl cyclases 
(ACs) and the degradation by phosphodiesterases (PDEs), respectively. Accordingly, 
cAMP levels are highly dynamic and the temporal patterns of cAMP are critical 
regulators of cell function as shown for example in pancreatic cells (Willoughby and 
Cooper, J. Cell Sci. 2006; Willoughby et al., J. Biol. Chem. 2010; Halls and Cooper, 
Cold Spring Harb. Perspect. Biol. 2011).  
cAMP itself can elicit a wide variety of cellular responses, which are mainly dependent 
on the cell-type (see Figure 1). Most prominently cAMP leads to the activation of PKA 
(protein kinase A) where it binds to specific binding domains. In heart muscle cells this 
can result in the phosphorylation and activation of Ca
2+
 channels, which in turn will 
result in higher intracellular [Ca
2+
] and increased myocyte contraction (positive 
inotropy). PKA-dependent phosphorylation of the small heat-shock protein Hsp20 
protects the heart from damage caused by ischemia (Edwards et al., Biochem. Soc. 
Trans. 2012). PKA can also phosphorylate Complex I of the respiratory chain of the 
mitochondria (Papa et al., FEBS Lett. 2012) and thereby regulate oxidative energy 
production. In the liver, PKA-phosphorylation will subsequently activate a 
phosphorylase and thereby increase the conversion of glucagon into glucose (Sutherland 
and Robison, Pharmacol. Rev. 1966; Gancedo, Biol. Rev. Camb. Philos. Soc. 2013). 
Apart from the activation of PKA cAMP can also directly activate HCN-channels 
(hyperpolarisation-activated cyclic-nucleotide-modulated channels), which in the heart 
will result in positive chronotropy (Ludwig et al., Nature 1998; Santoro et al., Cell 
1998). Activation of these channels by cAMP leads to a faster diastolic depolarisation 
of the membrane potential, subsequently decreasing the time to the next action 
potential. Furthermore, cAMP signalling is part of the circadian rhythm which, among 
others, influences pancreatic islet insulin release (Peschke, J. Pineal Res. 2008). This 
effect is regulated through melatonin, whose receptor couples Gi-proteins. 
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Another effector of cAMP is Epac (exchange protein directly activated by cAMP, 
official name RAPGEF3). It mediates cAMP effects independent of PKA-
phosphorylation and ion channels. It is alternatively referred to as cAMP-regulated 
guanine nucleotide exchange factor (cAMPGEF) (Holz et al., J. Physiol. 2006). Two 
isoforms have been identified so far: Epac1 and Epac2, named after their respective 
number of cAMP binding domains. A main effector of Epac is Rap (small molecular 
weight GTPase), whose activation triggers further downstream events. In the heart, 
Epac is necessary for the full effect of β-adrenergic stimulation, as it will activate Rap, 
which in turn activates CaMKII (Ca
2+
/calmodulin-dependent protein kinase II) via 
PLCε and PKCε (phospholipase C and protein kinase C, respectively). This will 
ultimately result in the phosphorylation of the Ryr2 (Ryanodin receptor type II) and 
PLB (phospholamban), thereby increase Ca
2+
 release from the SR and add to the Ca
2+
-
induced Ca
2+
 release (CICR), which is the main mediator of excitation-contraction 
coupling (Gloerich and Bos, Annu. Rev. Pharmacol. Toxicol. 2010). In case of chronic 
β-adrenergic stimulation, the heart will undergo remodelling and hypertrophy. This can 
also be linked to Epac via calcineurin and CaMKII (Gloerich and Bos, Annu. Rev. 
Pharmacol. Toxicol. 2010; Metrich et al., Pflugers Arch. 2010). On the other hand, 
Epac can be protective against hypertrophy by inhibiting ERK5-induced (extracellular 
signal-regulated kinase 5) hypertrophic changes (Gloerich and Bos, Annu. Rev. 
Pharmacol. Toxicol. 2010). 
Apart from its function in the heart Epac has been reported to attribute to the secretion 
of insulin and neurotransmitters (Gloerich and Bos, Annu. Rev. Pharmacol. Toxicol. 
2010), as well as the regulation of the endothelial barrier function, which in turn might 
control excessive migration of leukocytes in inflammatory diseases (Metrich et al., 
Pflugers Arch. 2010). Furthermore, there is growing evidence for Epac being involved 
in kidney diseases (Patschan et al., Am. J. Physiol. Renal Physiol. 2010). 
1.4.1 Compartmentalisation of cAMP 
One could assume cAMP to diffuse freely within the cell, because of its rather small 
size and hydrophilicity. However, there is growing evidence for different cAMP 
compartments in which the individual pathways are organised. In cardiac myocytes 
β1-AR results in a cAMP increase throughout the whole cell, while the closely related 
β2-AR only triggers localised cAMP generation (Nikolaev et al., Circ. Res. 2006). ACs 
can be targeted to raft and non-raft membrane domains (Cooper, Biochem. Soc. Trans. 
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2005), which could also enhance the interaction with other proteins of the signalling 
pathway and thereby reduce the diffusion of cAMP. Lately, AC5 was shown to be 
mainly located in T-tubules of myocytes, whereas the closely related AC6 is localised 
more globally (Timofeyev et al., Circ. Res. 2013). Last, but not least, AKAPs (A-kinase 
anchoring proteins) can bind a wide variety of proteins and thereby integrate different 
proteins into signalling complexes (Kritzer et al., J. Mol. Cell. Cardiol. 2012). The 
recruitment of PKA, PDEs, Epac and maybe further proteins to these complexes would 
ensure close proximity of the signalling partners and the presence of PDEs could avoid 
activation of adjacent complexes through the immediate degradation of otherwise freely 
diffusible cAMP (Edwards et al., Semin. Cell Dev. Biol. 2012). The 
compartmentalisation of cAMP is presumably a potent mechanism to spatially and 
temporally confine the signalling cascades. 
1.5 Real-time measurements using Förster Resonance Energy Transfer 
(FRET) 
Biochemical studies have revealed a lot of important information about adenylyl 
cyclases, their structure and interaction with G-proteins. However, these studies are 
mostly based on in vitro methods and thereby restricted to steady-state interactions. The 
present study aimed to investigate dynamic changes in the G-protein/AC-interaction in 
living cells. FRET-microscopy has been used to investigate protein/protein-interaction 
in cells and therefore provided a promising tool. The development of an in vivo 
technique would further provide new options for the research on ACs in settings closer 
to the physiological environment of the investigated partners. 
Förster or Fluorescence Resonance Energy Transfer is the radiation-free transfer of 
energy from an excited donor fluorophore to a non-excited acceptor fluorophore. The 
German scientist Theodor Förster described and calculated this phenomenon in 1948 
(Förster, Annalen der Physik 1948). Based on his calculations, the FRET-efficiency E is 
dependent to the sixth power of the distance between the fluorophores r and the so-
called Förster radius R0: 
  
 
  (
 
  
)
  
The Förster radius R0 describes the distance between the two fluorophores where the 
FRET efficiency is half-maximal. 
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Apart from the distance between the two interacting fluorophores, two other aspects are 
crucial for the energy transfer. Firstly, efficient FRET needs a certain spectral overlap of 
the donor emission and acceptor excitation spectra. Secondly, the fluorophores’ 
orientation should align the actual fluorescent planes (if existent). The second aspect is 
important for FRET between derivatives of GFP, the green fluorescent protein 
(Shimomura et al., J. Cell. Comp. Physiol. 1962; Tsien, Annu. Rev. Biochem. 1998), as 
these have a distinct fluorophore plane inside their β-barrel. For a long time cyan- and 
yellow-fluorescent mutations of GFP (CFP and YFP, respectively) have been used, 
because of the efficient FRET. In order to increase the fluorophores’ brightness, several 
variants have been cloned. In this study, enhanced CFP (eCFP; abbreviated as CFP 
hereafter) and Cerulean (Cer) were used as FRET-donors. The FRET-acceptor used was 
a variant of enhanced YFP, which had been mutated to increase its brightness (eYFP 
F46L/L68V; abbreviated as YFP in the following). 
Typically FRET is determined by either acceptor bleaching, sensitised emission, 
fluorescence lifetime or fluorescence anisotropy (Ishikawa-Ankerhold et al., Molecules 
2012). 
For fluorescence lifetime measurements (FLIM, fluorescence lifetime imaging 
microscopy) the exponential decay of the donor fluorescence is determined. This is 
influenced by the chemical environment of the fluorophores, but not by their 
concentration (Becker, J. Microsc. 2012). The presence of a FRET-acceptor changes the 
donor’s environment and reduces the fluorescence lifetime. FRET-detection by means 
of fluorescence anisotropy relies on polarisation of excitation and emission light. 
Fluorophores within the plane of the polarised light can be excited, but only emission of 
properly aligned FRET-acceptors can be recorded (Ishikawa-Ankerhold et al., 
Molecules 2012). 
Acceptor photobleaching was used in these studies to determine FRET under non-
stimulated conditions. Direct excitation of the acceptor fluorophore with high-intensity 
light irreversibly bleaches the fluorescent protein and thereby destroys the FRET-pair. 
Subsequently the donor fluorophore can no longer transfer energy to the acceptor and its 
fluorescence intensity will increase if FRET occurred before the bleaching. This method 
is only applicable for steady-state experiments. To dynamically investigate the 
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interaction between fluorescently labelled proteins, a method closely related to 
sensitised emission was applied. 
During sensitised emission the donor is excited and the fluorescence of the acceptor is 
monitored, as it will only occur – under ideal conditions –, if there is FRET between 
donor and acceptor. In reality, one always has to consider the spectral cross-talk 
between the fluorophores. The donor fluorescence spectrum will usually “tail” and 
therefore reach into the acceptor’s emission channel, a phenomenon that is referred to as 
“bleed-through”. In addition, the acceptor can often be excited by the donor excitation 
light. This is referred to as “false excitation” (refer to methods section for further details 
on spectra and correction factors). During the actual experiments CFP was excited, the 
CFP- and YFP-fluorescence were recorded simultaneously and the according ratio of 
YFP- over CFP-fluorescence was calculated. Low FRET would result in strong 
fluorescence of CFP and weak emission of YFP. Accordingly, a low FRET-ratio would 
be observed. In case of high FRET, the fluorescence of YFP would increase, while 
CFP-emission would decrease, resulting in an increase of the FRET-ratio (Figure 5).  
 
Figure 5: FRET-changes during sensitised emission 
The sketch illustrates, that FRET only occurs if the acceptor (YFP) is close enough to the donor 
(CFP). 
Using the methods based on sensitised emission, major parts of the signalling pathway 
from GPCR activation to the generation of second messengers have been investigated 
(see Lohse et al. (Pharmacol. Rev. 2012) for a recent review). The following sections 
only list the investigations and assays relevant for this study.  
1.5.1 Real-time detection of G-protein activity 
According to older textbook knowledge, activation of the G-protein will result in the 
dissociation of the α- from the βγ-subunit. If there is FRET between the subunits prior 
to stimulation, this should be decreased if not totally lost upon activation and 
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subsequent dissociation of the G-protein. All the G-protein-assays available show FRET 
under non-stimulated conditions. 
Upon activation of the Gs-protein, the FRET-signal decreases (Hein et al., J. Biol. 
Chem. 2006), within less than one second. The decrease in the FRET-signal could 
represent the dissociation of the Gα- and Gβγ-subunits. However, the loss in FRET 
could also be due to an activity-dependent conformational change, that results in an 
increased fluorophore distance or orientation that does not favour FRET. Contrastingly, 
activation of the Gi1-protein will result in an increase in FRET between the subunits 
(Bünemann et al., Proc. Natl. Acad. Sci. U. S. A. 2003). This argues against the 
hypothesis that the subunits will completely separate upon activation. The activation of 
Gi-proteins also occurs fast, the according time course being in the same range as 
Gs-protein activation. 
1.5.2 Real-time detection of cAMP 
The development of FRET-based sensors like Epac1-camps allowed for the dynamic 
measurement of cAMP in single living cells (Nikolaev et al., J. Biol. Chem. 2004). This 
sensor consists of a cAMP binding domain from Epac (exchange protein directly 
activated by cAMP; official name RAPGEF3), which is coupled to YFP and CFP. In the 
inactive, i.e. non-cAMP-bound state, the sensor has a closed conformation where the 
fluorophores are in close proximity and accordingly high FRET is observed. FRET 
decreases upon generation of cAMP. Presumably, the hinge region of the Epac1 
fragment opens upon binding of cAMP and the distance between CFP and YFP 
increases (Figure 6). 
 
Figure 6: Presumed mode of action of the FRET-based cAMP sensor Epac1-camps 
If no cAMP is bound, the sensor will show a closed conformation. The fluorophores are in close 
proximity and high FRET will be observed. Binding of cAMP to the sensor’s hinge region will 
open the sensor and thereby increase the distance between CFP and YFP. Accordingly, the 
sensor will now yield low FRET. 
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Prior to the development of sensors like this, the detection of cAMP mainly relied on 
radioactive or biochemical methods (Dessauer, Methods Enzymol. 2002). These assays 
are suitable for steady-state experiments, as the cells are usually lysed for the detection. 
It was not possible to determine dynamic changes of cAMP, especially not in tissues. 
The use of Epac1-camps revealed a half-time of about 30 s for the generation of cAMP 
(Nikolaev et al., J. Biol. Chem. 2004). This is a rather slow process, compared to the 
previously described steps (receptor activation below 100 ms, G-protein activation 
below 1 s). Whether the interaction between the G-proteins and ACs or the generation 
of cAMP by the ACs is the limiting step in this pathway remained unclear. 
The pharmaceutical industry has used bioluminescence-based cAMP assays in uHTS-
applications (ultra high-throughput screening) (Wunder et al., Mol. Pharmacol. 2008). 
These assays show very high sensitivity in comparison to the classical cAMP detection 
methods and also allow kinetic investigation of cAMP levels. Being screening assays, 
they do not allow observation in single cells, though. During these studies, collaboration 
with Dr. Frank Wunder (Bayer Research Center, Wuppertal) was established, as these 
assays provided tools for the fast characterisation of the AC-constructs. 
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1.6 Aim of this study 
Most parts of the signalling pathway from GPCRs to cAMP regulation had already been 
investigated with high temporal resolution. However, the direct interaction between 
G-proteins and their effectors has not been studied in such detail. Research on ACs has 
been limited to steady-state assays and interaction dynamics of G-proteins and ACs 
remained elusive. This study was designed to develop a FRET-based assay to 
dynamically investigate the interaction between AC5 and different G-protein subunits in 
living cells. The FRET-technique was chosen, because it combined high temporal 
resolution with the possibility to measure the interaction in living cells. This allows 
biochemical investigation of the G-protein/AC-interaction in vivo and also complements 
the already available microscopic methods for the signalling pathway from GPCR to 
second messenger. Most available assays to analyse cAMP generation cannot properly 
resolve Gi-protein-dependent regulation of ACs. The new assay was therefore 
especially intended to investigate Gi-protein/AC-interaction in combination with 
existing FRET-based cAMP-assays. There were also previous unexplained reports on 
the high sensitivity of cAMP-dependent over Gi-protein-dependent pathways (Li et al., 
J. Gen. Physiol. 1994). Furthermore, AC5 had been reported to be selectively regulated 
through dopamine D3 receptors (Robinson and Caron, Mol. Pharmacol. 1997). In 
combination, both effects hinted at a high sensitivity of ACs towards Gi-protein-
mediated inhibition. However, these investigations had been based on readouts 
downstream of Gi-protein and AC5. Using the new assay, this study aimed to reveal 
potential mechanisms underlying the high sensitivity through investigating the 
molecular interaction of the two signalling partners. 
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2 Material and Methods 
The sections 2.2.4, 2.2.5, 2.2.6 and 2.2.7 of this chapter are also part of the author’s own 
manuscript, which is under revision at the Biochemical Journal (BJ2013/0554) at the 
time of this publication. 
2.1 Material 
2.1.1 Enzymes 
Enzymes for the Gateway cloning system were purchased from Invitrogen. Restriction 
enzymes and ligase were purchased from NEB (New England Biolabs) or Fermentas, as 
well as the polymerases Vent, Pfu and Taq. Further polymerases were purchased from 
Biozyme (Phusion) or Peqlab (Kappa-HiFi). 
2.1.2 Antibodies (Western-Blot and immunofluorescence) 
antibody supplier target clonality dilution experiment antibody 
species 
       
A cyclase 
V/VI 
(C-17) 
Santa Cruz 
(SC-590) 
AC5 poly 1:100-
1:500 
WB/IF rabbit 
A cyclase 
V (P-20) 
Santa Cruz 
(SC-74301) 
AC5 poly 1:100 WB goat 
HA.11 
Clone 
16B12 
Covance 
(MMS-101P) 
HA-tag mono 1:500 WB/IF mouse 
anti-actin 
clone C4 
Merck 
Millipore 
(MAB1501) 
actin mono 1:100,000 WB mouse 
anti-GFP Rockland 
(600-101-215) 
GFP poly 1:200 WB goat 
HRP-linked 
anti-mouse 
Vector 
Laboratories 
(PI-2000) 
primary 
AB (anti-
mouse) 
poly 1:4,000 WB horse 
HRP-linked 
anti-rabbit 
Vector 
Laboratories 
(PI-1000) 
primary 
AB (anti-
rabbit) 
poly 1:4,000 WB goat 
HRP-linked 
anti-goat 
Vector 
Laboratories 
(PI-9500) 
primary 
AB (anti-
goat) 
poly 1:4,000 WB horse 
DyLight 
650 linked 
anti-mouse 
Thermo 
Scientific 
(84545) 
primary 
AB (anti-
mouse) 
poly 1:200 IF goat 
DyLight 
650 linked 
anti-rabbit 
Thermo 
Scientific 
(84546) 
primary 
AB (anti-
rabbit) 
poly 1:200 IF goat 
Table 1: Antibodies used in this studies 
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2.1.3 Oligonucleotides 
Oligonucleotides (“primers”) for the Gateway-Cloning System were designed according 
to the manufacturer’s protocol and with the help of Invitrogen’s Vector NTI Software 
Suite (at the time of the primer design the software was free for academic users). 
2.1.4 Plasmids 
The following plasmids were either already published and available in the lab or were 
bought from the specified manufacturer. 
plasmid species
(1)
 origin or published vector 
    
YFP-hAC5 human Carmen W. Dessauer 
(University of Texas, Houston, Texas) 
pcDNA3 
AC2 rat Viacheslav O. Nikolaev (Würzburg) pcDNA3 
AC4 mouse Viacheslav O. Nikolaev pcDNA3 
AC6-CFP dog Viacheslav O. Nikolaev pcDNA3 
Epac1-camps human Viacheslav O. Nikolaev 
(Nikolaev et al., J. Biol. Chem. 2004) 
pcDNA3 
pcDNA3  Invitrogen pcDNA3 
Gαi1 C351I rat (Wise et al., Biochem. J. 1997) pcDNA3 
Gαi1-YFP C351I rat (Bünemann et al., Proc. Natl. Acad. Sci. 
U. S. A. 2003) 
pcDNA3 
Gαi1-CFP C351I rat Cloned analogous to Gαi1-YFP pcDNA3 
Gβ1 human (Bünemann et al., Proc. Natl. Acad. Sci. 
U. S. A. 2003) 
pcDNA3 
Gβ1-Cer human (Frank et al., J. Biol. Chem. 2005) pcDNA3 
Gγ2 bovine (Bünemann et al., Proc. Natl. Acad. Sci. 
U. S. A. 2003) 
pcDNA3 
Gγ2-CFP bovine (Bünemann et al., Proc. Natl. Acad. Sci. 
U. S. A. 2003) 
N1-eCFP 
(Clontech) 
Gαs rat (Hein et al., J. Biol. Chem. 2006) pcDNA1, 
subcloned 
to pcDNA3 
Gαs-YFP human (Hein et al., J. Biol. Chem. 2006) pcDNA1, 
subcloned 
to pcDNA3 
Gαs-Cer human Cloned analogous to Gαs-YFP pcDNA1, 
subcloned 
to pcDNA3 
Gαq mouse (Hughes et al., J. Biol. Chem. 2001) pcDNA3 
Gαq-YFP mouse (Hughes et al., J. Biol. Chem. 2001) pcDNA3 
Gαq-CFP mouse Cloned analogous to Gαq-YFP pcDNA3 
Gα0-YFP rat (Hommers et al., J. Biol. Chem. 2010) pcDNA3 
α2A-AR (HA-
tagged) 
mouse (Bünemann et al., Proc. Natl. Acad. Sci. 
U. S. A. 2003) 
pcDNA3 
α2A-AR-YFP mouse (Krasel et al., J. Biol. Chem. 2005) pcDNA3 
β2-AR
(2)
 human (Krasel et al., J. Biol. Chem. 2005) pcDNA3 
M2-AChR human (Roseberry et al., Mol. Pharmacol. 2001) pGES 
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M3-AChR human Obtained from Missouri S&T cDNA 
Ressource Center (www.cdna.org) 
pcDNA3 
A2A-AdoR human (Hein et al., J. Biol. Chem. 2006) pcDNA3 
RGS4 (HA-
tagged) 
rat Moritz Bünemann 
derived from (Doupnik et al., Proc. Natl. 
Acad. Sci. U. S. A. 1997) 
pcDNA3 
mGFP-10-
sREACh-N3 
 addgene.org (#21947) 
(Murakoshi et al., Brain Cell Biol. 2008) 
mGFP-C1 
(Clontech) 
YFP*-β2-AR-
CFP
(2)
 
human Sandra Dorsch 
(Dorsch et al., Nat. Methods 2009) 
pcDNA3 
CD86-YFP human (Dorsch et al., Nat. Methods 2009) pcDNA3 
membrane 
associated 
YFP
(3)
 
 (Hein et al., EMBO J. 2005) pcDNA3 
membrane 
associated CFP
(3)
 
 cloned analogous to membrane 
associated YFP 
pcDNA3 
TurboFP635 
(“Katushka”)(4) 
 Evrogen FP722 
(Shcherbo et al., Nat Methods) 
Clontech-N-
like 
Table 2: Plasmids used during this study 
(1) No species is indicated for fluorescent proteins and empty vector. (2) Plasmid contains 
polymorphisms 16-Arg, 27-Gln and 164-Thr. (3) Membrane anchor sequence: MGCINSKRKD. 
(4) “Katushka” is not derived from GFP and will not be detected by antibodies against GFP. 
2.1.5 Cell culture media 
Cell culture media and supplements were obtained from PAA (Pasching, Austria). The 
normal culturing medium was Dulbecco’s Modified Eagle Medium (DMEM) with 
4.5 g/L glucose, 10 % (v/v) fetal calf serum, 2 mM L-glutamine, 100 U/mL penicillin 
and 0.1 mg/mL streptomycin. 
2.1.6 Software 
The following software was used for the assigned purposes: 
 Plasmid sequences, alignments 
o VectorNTI (Invitrogen) 
o ApE – A plasmid Editor 
(http://biologylabs.utah.edu/jorgensen/wayned/ape/) 
o Serial Cloner (http://serialbasics.free.fr/Serial_Cloner.html)  
 Data analysis and statistics 
o Microsoft Excel 2007 or newer 
o GraphPad Prism 5 
o OriginLabs OriginPro 8 and 9 
 Picture/Image analysis and modification (cropping, range-adjusting, overlay) 
o ImageJ 1.46r (http://imagej.nih.gov/ij/) 
o Corel Photo-Paint X4 
 Figure optimisation for publishing 
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o CorelDraw X4 
Image acquisition on microscopes and the ChemiDoc (imaging-system for gels) was 
performed with the supplied software on the individual setups. Images were saved as 
Tiff or JPG to allow further analysis with ImageJ or Photo-Paint. 
2.2 Methods 
All buffers used in the following protocols are listed in section 2.2.8. 
2.2.1 Molecular biology 
2.2.1.1 Generation of competent E. coli 
Competent E. coli for plasmid production were prepared following a protocol modified 
from that published by Chung et al. (Chung et al., Proc. Natl. Acad. Sci. U. S. A. 1989). 
1. Plate bacteria on LB-agar and incubate overnight 
2. Pick a colony and grow bacteria in 10 mL LB-broth overnight (50 mL Falcon 
tube) 
3. Give 5-10 mL of suspension into a final volume of 250 mL LB-broth and grow 
to an OD600 of 0.3-0.6. This will typically take 1.5 to 4 h. 
4. Harvest bacteria by centrifugation at 5000 rpm and 4 °C for 10 min; resuspend 
gently in 25 mL ice-cold TSB 
5. Incubate for 1-2 h on ice 
6. Aliquot, freeze in liquid nitrogen and store at -80 °C 
2.2.1.2 Transformation of E. coli 
1. Thaw bacteria on ice. When completely thawed, mix 
amount ingredient 
  
20 µL 5x KCM-buffer 
80 µL water 
2 µL DNA 
100 µL competent cells 
2. Incubate 20 min on ice 
3. Incubate 10 min at RT 
4. Add 1 mL LB-broth 
5. Incubate 50 min shaking at 37 °C 
6. Optional: centrifugate for 30-60 s and resuspend in 50-200 µL LB-broth 
7. Plate 60-100 µL of 5. on ampicillin-containing LB-agar and incubate overnight 
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2.2.1.3 Plasmid preparation 
Medium-scale plasmid preparations (“Midi-Prep”) were carried out using Qiagen’s 
Plasmid Midi Kit according to manufacturer’s protocol with 100 mL of bacteria-
suspension grown overnight. 
Small-scale plasmid preparations (“Mini-Prep”) for control purposes were performed 
from 1.5 of 4 mL overnight suspension. The buffers P1, P2 and P3 from the Plamid 
Midi Kit (Qiagen) were used here as well. All centrifugation steps are performed in a 
desktop centrifuge for reaction tubes at maximum speed. 
1. Centrifuge 1.5 mL suspension for 20 s to sediment the cells; discard the 
supernatant 
2. Resuspend pellet in 300 µL buffer P1 
3. Add 300 µL buffer P2, mix and incubate 5 min at room temperature (RT) 
4. Add 300 µL buffer P3, mix well and centrifuge for 15 min at 4 °C 
5. Transfer 800 µL supernatant to a new reaction tube, add 750 µL n-propanol, mix 
and centrifuge for 15 min at 4 °C 
6. Remove supernatant carefully, dry the pellet and solve in 50 µL water 
The resulting DNA might not be pure enough for some further cloning steps (esp. 
digestion with EcoRI). In that case the plasmid-DNA should be cleaned further using a 
small column (e.g. from Qiagen’s QIAquick Gel Extraction Kit). 
2.2.1.4 Polymerase chain reaction (PCR) 
amount ingredient 
  
x µL template (1-5 ng) 
2 µL buffer 10x 
2 µL dNTP mix (2 mM each) 
1 µL forward primer (10 µM) 
1 µL reverse primer (10 µM) 
ad 20 µL water 
0.5-1 µL polymerase (Phu, Vent, Taq, Phusion, Kapa-HiFi) 
 The actual programming of the thermocycler needs to be adapted to the primers, 
template-size and the polymerase (according to manufacturer’s protocol). 
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2.2.1.5 Agarose gel electrophoresis 
In this study only gels of 1 % (m/v) agarose in TAE buffer were used. The agarose can 
only be dissolved, if the buffer is warmed. To allow UV-light detection of the DNA, 
ethidiumbromide (2 µL of a 10 mg/mL solution, Promega) was pipetted into the 
chamber immediately before pouring the warm gel-solution into the chamber. 
2.2.1.6 Cloning of plasmids 
2.2.1.6.1 xFP-labelled adenylyl cyclases 
The 3-fragment MultiSite Gateway Pro system (Invitrogen) was used to clone 
fluorescently labelled ACs. Using the ACs as the insert for the second/middle fragment, 
it was possible to easily add different fluorophores to either terminus. Primer-design 
was carried out according to the manufacturer’s protocol with the help of the software 
Vector NTI (Invitrogen, at that time free for academic users). To increase the linkers 
flexibility, four additional aminoacids were added. All the reactions were carried out 
according to the manufacturer’s manual, but the size of each reaction was reduced by 
50 % to save enzymes. Several so-called entry-clones were generated or provided 
(Table 3). Some entry clones and the empty vectors were provided by Sabine Merkle 
and Prof. Dr. Stefan Engelhardt. Further fluorescent entry clones were cloned. The final 
construct was recombined from the entry clones into the expression vector 
pT-RExT-DEST30. The amino acid sequence linking YFP and the ACs is 
AGAGHPTFLYKVA. The C-terminal linker contains the Stop-codon and has the 
amino acid sequence TTLYNKVV*. 
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name insert
(1)
 fragment cloned by 
    
Entry 5.11 AC5 2/middle me 
Entry 2.6 AC2 2/middle me 
Entry 4 #5 AC4 2/middle me 
Entry 6 #7 AC6 2/middle me 
 Katushka 1/N-term. me 
Entry DY.2 sREACh 1/N-term. me 
Entry YFP 1/4 YFP*
(2)
 1/N-term. Monika Frank 
Entry CFP 1/4 CFP 1/N-term. Monika Frank 
Entry Cer 1/4 Cer 1/N-term. Monika Frank 
Entry YFP 3/2 YFP* 3/C-term. Monika Frank 
Entry CFP 3/2 CFP 3/C-term. Monika Frank 
Entry Cer 3/2 Cer 3/C-term. Monika Frank 
Spacer 1-4 none
(3)
 1/N-term. Sabine Merkle, Stefan Engelhardt 
Spacer 3-2 none
(4)
 3/C-term. Sabine Merkle, Stefan Engelhardt 
Table 3: Entry-Clones generated or used in the Gateway cloning system 
The table lists all the fragments generated or used during the cloning of fluorescent AC-
constructs. The numbers in the names refer to the flanking recombination sites, which show the 
order 1-4-3-2. Accordingly the second or middle fragment is flanked by the sites 4 (N-terminus) 
and 3 (C-terminus). (1) N-terminal and middle fragments do not contain a Stop-codon. All the 
middle constructs contain a Start-Codon, though. (2) YFP* is an eYFP-variant: 
eYFP(F46L/L68V) (Start-codon not counted!). (3) This fragment does not contain any coding 
sequence. The Start-codon of the second fragment is used to start translation in this case. (4) 
This fragment only codes for a Stop-codon, positioned directly after the recombination site no. 
3. 
The constructs generated using this system are listed in the results section (Table 5). 
2.2.1.6.2 wild-type human AC5 in pcDNA3 
Dr. Carmen W. Dessauer (University of Texas, Houston) had kindly provided 
pcDNA3-YFP-hAC5. From this construct pcDNA3-hAC5 was cloned by standard 
restriction and ligation protocols (see below). The sites used were BamHI, NotI and 
XbaI. 
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2.2.1.7 Basic protocols for restriction and ligation 
2.2.1.7.1 Restriction 
amount ingredient 
  
1-2 µg plasmid 
0.5 µL per enzyme 
2 µL buffer 10x (according to enzyme) 
0.2 µL BSA 100x (according to enzyme) 
ad 20 µL water 
 Incubate for 60 min at 37 °C 
 Separate with agarose gel electrophoresis 
 Optional: clean plasmid fragment from gel using the Gel Extraction Kit (Qiagen) 
2.2.1.7.2 Ligation 
amount ingredient 
  
0,5-1 µL ligase 
1 µL buffer 10x 
 vector* 
 insert* 
ad 10 µL water 
*The amounts used vary depending on the size of vector and insert, the concentration of the 
respective solutions and the backbone/insert-ratio. 
 Incubate for 1-2 h at RT or at 14-16 °C over night 
 Transform into competent bacteria 
2.2.2 Biochemical approaches 
2.2.2.1 Western-Blotting 
The following protocol was derived from a general protocol available in the lab. The 
initial source remains unknown, though. The actually used antibodies are described in 
the results section at the according blots. 
HEK293T cells were transiently transfected as described in section 2.2.3 but instead of 
splitting the cells onto cover slips they were transferred to 10 cm culture dishes and 
incubated for another 24 h. The medium was removed and the dishes immediately 
frozen at -80 °C. 
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2.2.2.1.1 Lysate preparation (whole-cell lysates) 
1. Thaw dishes on ice, add 1 mL of lysis buffer 
2. Scrap cells, resuspend in the buffer and transfer to reaction tube 
3. Homogenise suspension for 30 s with the Ultra-Turrax (Model IKA T10 basic) 
4. Determine the amount of protein with Bradford’s reagent 
a. Optional: adjust the samples with lysis buffer to equal amounts of protein 
5. Add 5x sample buffer 
6. Heat samples to 95 °C for 15 minutes 
These lysates can be stored in the fridge for a few days. 
2.2.2.1.2 Lysate separation, blotting and detection 
1. Separate the lysates on 10 % SDS-PAGE (topped with a 3.5 % collection gel) 
a. 30 min at 60 V, then 100-120 V 
2. Wet PVDF membrane (Roche) in methanol, store in transfer buffer until 
sandwich with gel is built 
3. Transfer the proteins to PVDF membrane with either wet or semi-dry blotting. 
Wet blotting tends to transfer the proteins better to the membrane, especially 
larger proteins 
a. Caution: The stacking order is different for both methods, the transfer 
buffers contain different amounts of methanol 
b. Semi-dry: 60 min at 15 V; performed at RT 
c. Wet: 2 h at 200 mA, then 18 h at 20 mA; performed at 4 °C 
The following steps are performed on desktop shakers. 
4. Incubate with “milk” for 1 h at RT to block the membrane 
a. Some antibodies might need special sera to be incubated in. In this case 
the membrane is blocked with the same solution as used to dilute and 
incubate the antibody. 
5. Incubate with primary antibody (diluted in “milk”) over night at 4 °C 
6. Incubate 1 h at RT 
7. Wash with TBST (3x 5 min) 
8. Incubate with secondary HRP-labelled antibody (diluted in “milk”) for 1 h 
9. Wash with TBST (3x 15 min) 
10. Incubate in HRP detection solution (e.g. HRP-Juice PLUS, PJK) and detect 
bioluminescence with the Chemidoc system (BioRad). 
The membrane can be stripped and used for another antibody-detection. This procedure 
does not completely remove the already used primary antibodies, though. These steps 
are also performed on a shaker. 
11. Optional: Wash membrane with water (5 min) 
12. Incubate with stripping buffer for 5-15 min 
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13. Wash with PBS (purchased from PAA) and TBST (5 min each) 
14. Continue from point 4. (blocking) 
2.2.2.2 Immunofluorescence 
1. HEK293T cells were transfected and transferred to cover slips as described in 
section 2.2.3. 
2. Remove medium 
3. Wash cover slips with PBS (2x) 
4. Incubate with paraformaldehyde (4 % in PBS) for 30 min at RT 
5. Wash with PBS (3x) 
6. Block for 1 h (5 % FCS in PBS) 
7. Wash with PBS 
8. Incubate with primary antibody (diluted in blocking solution, see above) 
9. Wash with PBS (3x 5 min) 
10. Incubate with secondary antibody (fluorescently labelled) for 1 h (diluted in 
blocking solution) 
11. Wash with PBS (3x 5 min) 
2.2.3 Cell culture and transfections 
HEK293T cells were passaged every 2-3 days and cultured on 10 cm dishes. HEK293T 
cells were transfected using Effectene transfection reagent (Qiagen) according to the 
manufacturer’s protocol. In general two different transfection procedures were used. 
Initially a 3-day protocol (mainly in the experiments involving Gs-proteins) was 
applied, but was switched to a 4-day protocol in the later experiments. It was observed 
that the cells transfected with Gs-proteins become round and die, possibly because of 
some endogenous activity of the pathway. Performing transfections according to the 
3-day protocol reduced this effect. In contrast to this, the cells transfected with 
Gi-protein-involving pathways tolerate the 4-day protocol and show better membrane 
expression of YFP-AC5. The 4-days protocol also improved RGS4 expression in the 
later experiments. 
 
 
 
 
 
 Material and Methods 
31 
 
3-day protocol  4-day protocol 
day step  day step 
     
1, morning passage cells from 10 cm to 
6 cm dish 
(usually 0.75-1.0 mL of 
10 mL suspension) 
 1, morning passage cells from 10 cm 
to 6 cm dish 
(usually 0.3-0.5 mL of 
10 mL suspension) 
1, evening replace medium and 
transfect cells 
 2, morning replace medium and 
transfect cells 
2, morning stop transfection 
(i.e. change medium) 
 2, evening stop transfection 
(i.e. change medium)
(1)
 
2, evening split cells onto cover slips
(2)
  3, evening split cells onto cover slips 
3 measurement  4 measurement 
Table 4: Transfection protocols 
The 10 cm dish used on day 1 was about 80 % confluently grown with cells. (1) To prevent 
serum-derived stimulation of α2A-AR yohimbine (100 nM) was added to the medium from this 
point onwards. (2) Cover slips should be coated with poly-L-lysine to increase adherence of the 
cells. 
2.2.4 Fluorescence microscopy 
2.2.4.1 FRET-microscopy in single living cells 
FRET-measurements of transiently transfected HEK293T cells were performed about 
48-54 h after transfection at room temperature using an inverted microscope (eclipse Ti, 
Nikon) equipped with a 100x oil immersion objective (Plan Apo VC 100x/1.40 Oil 
∞/0.17 Dic N2, Nikon). A fast switching, xenon arc-based illumination system (Lambda 
DG-4, Sutter Instrument) was used as light source. The following filters (all Chroma) 
were used: ET 430/24x (CFP excitation) or ET 500/20x (YFP excitation), T455LP 
(long-pass beamsplitter to collect combined fluorescence of CFP and YFP) or 
CFP/YFP-beamsplitter plus CFP/YFP emission filter (Cat.No. 59017bs and 59017m), 
z488/800-1064rpc (beamsplitter to separate CFP and YFP emission), ET 480/40 (CFP 
emission) and HC 534/20 (YFP emission). The last three components were set in an 
Optosplit II (Cairn Research) to simultaneously record CFP and YFP fluorescence using 
a fast CCD camera (Evolve512, Roper Scientific). Microscope, camera and DG-4 were 
controlled using NIS-Elements AR (laboratory Imaging). In order to synchronise 
camera and lamp an additional trigger-box was supplied by Nikon. Cells were 
continuously superfused with buffer (see section 2.2.8.1) or buffer containing agonist in 
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different concentrations using a fast-switching 8 channel valve-controlled pressurised 
perfusion system with solenoid valves (Ala-VC³-8SP, Ala Scientific Instruments). For 
FRET-measurements CFP and YFP emission were recorded simultaneously while cells 
where excited with 430 nm. Depending on the fluorescence intensity, the illumination 
time was set to 20-40 ms at an interval of 500 ms or 2 s in the Epac1-camps 
experiments. Some of the kinetic experiments were performed at a sampling rate of 
33 Hz. This is indicated in the respective figures. The lamp was set to lowest intensity 
to prevent bleaching. Cell fluorescence was recorded at 488 ± 20 nm (F488 for CFP) and 
534 ± 10 nm (F534 for YFP) and corrected for background fluorescence, resulting in FCFP 
and FYFP. To determine FRET, FYFP was additionally corrected for bleed-through of 
CFP fluorescence into the F534-channel and direct excitation of YFP at 430 ± 12 nm 
excitation was subtracted (refer to section 2.2.4.5 for a detailed description of this). The 
resulting fluorescence was divided by FCFP and 
    
    
 is referred to as “FRET-ratio”. In 
the course of this work, ratio-traces will usually be presented by themselves, but it was 
verified that all changes in FRET-ratio were accompanied by opposing movements of 
the individual fluorescence traces. 
2.2.4.2 Donor recovery after acceptor photobleaching 
Cells were kept in buffer without agonist during the bleaching process. Making use of 
the CFP/YFP-filters described above we collected CFP fluorescence during a 6 minute 
bleaching process for YFP. Fluorescence was recorded every 5 s. Between recordings 
the lamp was set to permanent YFP excitation (500 ± 10 nm) at the highest possible 
intensity to bleach the FRET-acceptor. The relative FCFP change before (FCFP,0) and after 
bleaching (FCFP) was evaluated as 
           
      
. 
2.2.4.3 Quantification of relative expression levels by means of fluorescence 
We used the previously published construct YFP-β2-AR-CFP (Dorsch et al., Nat. 
Methods 2009) for calibration of the stoichiometry of relative expression levels of CFP 
and YFP. This construct bears the same fluorophores used in YFP-AC5 and Gαi1-CFP, 
which allows for fluorescence comparison. The fluorescence intensities for both 
fluorophores, individually excited, were recorded and corrected for background 
fluorescence. FCFP was divided by FYFP to calculate the calibration factor. To calculate 
the individual expression ratio, the FCFP/FYFP-ratio of the Gαi/AC5-FRET cells was 
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measured similarly and was divided by the calibration factor to determine the amount of 
Gαi1-CFP overexpression over YFP-AC5. 
2.2.4.4 Immunofluorescence and confocal microscopy 
Immunofluorescently labelled cells were imaged using an epifluorescence microscope 
(Leica DMI 6000B with a Leica DFC360 FX camera). Confocal pictures were acquired 
with a Leica SP5 confocal microscope using excitation wavelength of 405 nm (laser 
diode) and 514 nm (Ar-laser). 
2.2.4.5 Correction factors 
As mentioned in the introduction, FRET will only occur, if the excitation spectrum of 
the acceptor fluorophore will overlap with the donor’s emission spectrum. The spectra 
usually do not follow Gaussian curves and therefore spectral crosstalk between the 
fluorophores will be observed in varies degrees. “Tailing” of donor emission into the 
channel used to detect acceptor emission is referred to as “bleed-through”. Furthermore, 
acceptor excitation by wavelengths intended to excite the FRET-donor is termed “false 
excitation”, because in this case the acceptor’s fluorescence is not occurring through 
FRET from the donor. Figure 7 depicts the excitation and emission spectra of CFP and 
YFP, respectively. 
 
Figure 7: Excitation and emission spectra of fluorescent proteins 
This shows the normalised excitation (ex) and emission (em) spectra for the cyan and yellow 
fluorescent protein, respectively. The grey fields indicate (1) CFP excitation, (2) YFP false 
excitation and (3) CFP emission recorded. The recorded YFP emission consists of (4) CFP 
bleed-through into the channel intended to record YFP fluorescence and (5) YFP fluorescence 
induced by FRET. (All fields are indicated according to the filters installed on the Nikon 
microscope; refer to section 2.2.4.1 for further details).  
To allow for the correction of the spectral cross-talk, the following factors have to be 
measured. Because they are influenced by the spectrum of the light-source, as well as 
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e.g. filters and lenses, they have to be determined, if the bulb or any other components 
in the light-path have been changed. 
2.2.4.5.1 CFP fluorescence bleed-through into F534-channel 
HEK293T cells are transiently transfected with only one CFP-containing plasmid (e.g. 
membrane associated CFP). Cells are measured on the microscope as described in 
section 2.2.4.1 for the actual FRET experiments. F488 and F534 are recorded and 
corrected for background fluorescence. The correction factor for bleed-through is 
calculated by dividing F534 by F488. At the time of this study, this factor was about 0.4 
(Nikon-Setup with DG4). 
2.2.4.5.2 False excitation of YFP at 430 ± 12 nm 
HEK293T cells are transfected with an YFP-containing plasmid. The fluorescence F534 
is recorded for excitation at 430 ± 12 nm (filter setting 455LP) and 500 ± 10 nm (filter 
setting CFP/YFP dual band filter). Both F-values are corrected for background and 
F534(430) is divided by F534(500). The according value was in the range of 0.05 at the time 
of this study. 
2.2.5 Electrophysiology 
The according experiments were performed by Dr. Andreas Rinne in a collaborative 
effort. 
Patch pipettes (resistance 2 MΩ to 5 MΩ) were manufactured using borosilicate glass 
capillaries (GL150F-10, Havard Apparatus) with a horizontal pipette puller (P87, Sutter 
Instruments). During experiments, cells were continuously superfused with extracellular 
buffer consisting of (in mM): KCl 20, NaCl 122, MgCl2 1, CaCl2 0.5 and HEPES 10 
(pH 7.4 with NaOH). The intracellular solution was composed of (in mM): K
+
-aspartate 
100, KCl 40, NaCl 5, MgCl2 7, EGTA 2, GTP 0.25, Na
+
-ATP 5 and HEPES 20 (pH: 7.2 
with NaOH). G-protein-activated inwardly rectifying K
+
 (GIRK) channels of HEK293T 
cells expressing α2A-AR and GIRK1/4-subunits were activated by application of NE-
containing solutions. Corresponding whole-cell GIRK currents were recorded in the 
inward direction (Vhold: -90 mV, calculated EK: -48 mV) using an EPC 7 amplifier with 
an ITC-16 interface and Patchmaster software v2.52 (all HEKA). To identify GIRK 
currents, background-subtracted I/V-relationships were obtained by applying fast 
voltage ramps (-120 mV to +60 mV within 500 ms) in the absence and presence of NE. 
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2.2.6 Bioluminescence-based cAMP-assay 
The assay has been described before (Wunder et al., Mol. Pharmacol. 2008) and was 
performed in a collaborative effort with Dr. Frank Wunder at Bayer Research Center in 
Wuppertal. In general, this assay uses aequorin with its cofactors coelenterazine and 
Ca
2+
 to generate bioluminescence. The activation of ACs results in an increase in 
cAMP, which in turn opens CNG-channels (cyclic nucleotide-gated channels). 
Subsequently Ca
2+
 can enter the cells, which are kept for a brief period in Ca
2+
-free 
tyrode. The CNG-channel is opened according to the amount of generated cAMP, hence 
increasing amounts of cAMP will result in a higher portion of open channels, which in 
turn increases the Ca
2+
-influx and yields higher bioluminescence. 
2.2.7 Data analysis and statistics 
All FRET-recordings were corrected for photobleaching by subtracting a 
monoexponential baseline using OriginPro (OriginLab), unless stated otherwise. Signal 
amplitudes were calculated as agonist-induced alteration of the FRET-signal 
(Δ(FYFP/FCFP)). As the Gαi/AC5-FRET recordings could not be fitted properly to simple 
exponential equations, we determined t0.5-values directly from the traces. In all cases t0.5 
was determined as the time to reach half of the maximally evoked FRET-amplitude 
after agonist exposure or withdrawal. Application of saturating concentrations of NE 
resulted in an additional increase in the FRET-ratio of the Gαi/AC5-FRET after agonist 
withdrawal before recovering to baseline as seen for example in Figures 18, 20 and 24. 
Interestingly, this transient increase resulted in a comparable amplitude as the FRET-
change of the highest concentration that did not show this effect (usually a 
concentration below 10 nM NE). Increasing concentrations of NE reduced the actual 
amplitude of the agonist-induced FRET-increase, but did not affect the total amplitude 
of the transient (compare to Figure 24). We therefore hypothesised an inhibitory effect 
of the receptor as previously reported (Hommers et al., J. Biol. Chem. 2010). In order to 
avoid contribution of this unknown inhibitory component in the concentration-response 
experiments, we measured the peak value of this transient as the total amplitude of the 
agonist-induced FRET-change at the given concentration. Most likely because of 
desensitisation effects we sometimes observed an additional reduction of the total 
amplitude for 1 µM NE in the Gαi/AC5-FRET, resulting in bell-shaped concentration-
response curves (Figure 24). In those experiments we normalised to the next lower 
concentration and omitted the 1 µM NE-value during sigmoidal fitting. 
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To quantify Western-Blots Tiff-images acquired with the ChemiDoc were analysed 
using ImageJ (1.46r; http://imagej.nih.gov/ij/). A rectangular-shaped region of interest 
was placed on each band and raw intensities were measured. An additional region of 
interest of the same size was placed over an empty part of each band to allow for 
background correction. The obtained intensity values were analysed with Excel 2010 
(Microsoft Corporation). 
Statistics were obtained using GraphPad Prism and OriginPro by t-test or ANOVA with 
post-hoc tests as indicated in the individual figure legends. 
2.2.8 Buffers 
Where buffers were prepared in water, ultra-filtered water (Ultra Clear UV plus, 
Reinstwassersystem; SG Wasseraufbereitung, Barsbüttel, Germany) was used, as this 
was the highest quality available in the lab. The quality is comparable to double distilled 
water. 
PBS was purchased from PAA. 
This section lists x-fold stock solutions for some buffers. Unless otherwise specified, 
the according working solutions (1x solutions) were used in the actual experiments. 
2.2.8.1 “FRET” buffer 
amount ingredient 
  
137 mM NaCl 
5.4 mM KCl 
10 mM HEPES 
2 mM CaCl2 
1 mM MgCl2 
 water 
 adjust pH to 7.4! 
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2.2.8.2 LB-broth and LB-agar (bacterial media) 
amount ingredient 
  
1.0 % Peptone 
0.5 % yeast extract 
1 % NaCl 
 water 
 for agar-preparation add 1.5 % agar 
 autoclave medium 
 The powdered ingredients can be purchased as premixed bulk (e.g. from 
AppliChem). The mix is often cheaper than the individual ingredients. 
2.2.8.3 TSB (transformation and storage buffer) for competent bacteria 
amount ingredient 
  
10 % (m/v) PEG 3000 
5 % (v/v) DMSO 
20 mM MgSO4 or MgCl2 
 LB-broth 
 filter sterile 
 if desired store at -20 °C 
2.2.8.4 5x KCM buffer (for transformation of competent bacteria) 
amount ingredient 
  
500 mM KCl 
150 mM CaCl2 
250 mM MgCl2 
 water 
2.2.8.5 50x TAE buffer (agarose gel electrophoresis) 
amount ingredient 
  
242 g Tris (base) 
57.1 mL glacial acetic acid 
10 mL EDTA (0.5 M, pH 8) (see below) 
ad 1 L water 
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2.2.8.6 0.5 M EDTA 
amount ingredient 
  
35 g EDTA (water-free) 
~4 g NaOH 
ad 200 mL water 
 adjust pH to 8.0 with NaOH 
 EDTA will not dissolve until the pH is in the range of 8.0 
2.2.8.7 10x Agarose gel loading buffer (by Dr. Joachim Schmitt) 
amount ingredient 
  
40 % (m/v) glycerol 
10 mM EDTA 
10 mM Tris 
0.25 % (m/v) Orange G 
 water 
2.2.8.8 Lysis buffer for Western-Blot preparation 
amount ingredient 
  
20 mM Tris 
2 mM EDTA 
1 tablet/10 mL buffer proteinase inhibitor mix 
(cOmplete ULTRA Tablets Mini EDTA-free, Roche) 
 water 
2.2.8.9 Sample buffer (5x) for Western-Blot 
amount ingredient 
  
50 % (m/v) glycerine 
312.5 mM Tris-HCl 
10 % (m/v) SDS 
25 % (m/v) β-mercaptoethanol 
0.1 % (m/v) brome phenol blue 
 water 
 store at 4 °C 
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2.2.8.10 10x Running buffer for SDS-PAGE 
amount ingredient 
  
144 g glycine 
30 g Tris (base) 
10 g SDS 
ad 1 L water 
2.2.8.11 3.5 % collection gel for SDS-PAGE 
amount ingredient 
  
6.2 mL H2O 
2.5 mL 0.5 M Tris pH: 6.8 
0.1 mL 10 % SDS 
1.2 mL 30 % Acryl/bis 30 % 
0.05 mL APS 10 % 
0.01 mL TEMED 
2.2.8.12 10 % separation gel for SDS-PAGE 
amount for 1 gel ingredient 
  
4 mL H2O 
2.5 mL 1.5 M Tris pH: 8.8 
0.1 mL 10 % SDS 
3.3 mL 30 % Acryl/bis 30 % 
0.05 mL APS 10 % 
0.01 mL TEMED 
2.2.8.13 Blocking milk for Western-Blot 
amount ingredient 
  
5 % (m/v) skim milk powder 
 TBST 
2.2.8.14 Blocking solution for immunofluorescence 
amount ingredient 
  
5 % (v/v) FCS 
 PBS 
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2.2.8.15 10x TBS (and TBST) 
amount ingredient 
  
292 g NaCL 
24.2 g Tris (base) 
ad 1 L water 
 adjust pH to 7.5 
2.2.8.15.1 TBST 
1x TBS supplemented with 0.05 % (v/v) Tween 20 
2.2.8.16 10x Transfer buffers for wet and semi-dry blotting 
amount ingredient 
  
30 g Tris (base) 
144 g glycine 
ad 1 L water 
 adjust pH to 8.3 
1x transfer buffer for 
semi-dry blotting 
1x transfer buffer 
for wet blotting 
  
100 mL 10x stock 100 mL 10x stock 
100 mL methanol 200 mL methanol 
ad 1 L water ad 1 L water 
2.2.8.17 Stripping buffer for membranes 
amount ingredient 
  
15 g glycine 
1 g SDS 
10 mL Tween 20 
ad 1 L water 
2.2.8.18 Paraformaldehyde (for immune fluorescence) 
1. Heat 100 mL PBS to about 70 °C 
2. Add 4 g PFA 
3. Stir until dissolved 
4. Adjust volume back to 100 mL 
Filter, store at 4 °C  
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3 Results 
3.1 Generation of fluorescently labelled ACs 
In order to investigate the interaction between ACs and G-protein subunits by means of 
FRET the ACs had to be fluorescently labelled. Lacking detailed structural information 
from protein crystals it could not be determined, whether intramolecular loops would be 
suitable for insertion of the fluorescent tags. Therefore the fluorophores were attached 
to the N- or C-terminus. To clone the fluorescently labelled ACs the 3-Fragment 
Multisite Gateway Technology (Invitrogen) was chosen. Being a recombination based 
technique it abolished the need for unique restriction sites and therefore allowed easy 
addition of the fluorescent proteins to either terminus of the ACs. However, those 
recombination sites encode for linkers of at least 10 amino acids, including a flexibility-
reducing prolin. For compensation, four flexible amino acids were added (see methods 
section for further details) 
Several labelled AC-constructs were generated as listed in Table 5. Functional and/or 
regulatory impairments of the labelled enzymes, especially of those with C-terminal 
labels, could not be excluded prior to cloning. The large variety of constructs was 
cloned to provide enough options for identifying functional ones. 
As the constructs are generally built the same way, the representative plasmid maps 
shown in Figure 8 apply to the other constructs accordingly. 
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N-terminus AC C-terminus clone name published as 
     
YFP*
(1)
 
type V spacer 
Y5.9 YFP-AC5 
Cerulean Cer5  
CFP
(2)
 C5.11  
spacer type V 
YFP* 5Y.6  
Cerulean 5Cer  
CFP 5C.1  
TurboFP-635 
(Katushka) 
type V spacer Kat-AC5  
sREACh (“dark YFP”) type V spacer D5.2 sREACh-AC5 
YFP* 
type VI spacer 
Y6.5  
CFP C6.3  
spacer type VI 
YFP* 6Y.1  
Cerulean 6Cer.3  
CFP 6C.4  
YFP* 
type II spacer 
Y2.6  
Cerulean Cer2.3  
CFP C2.4  
spacer type II 
Cerulean 2Cer.6  
CFP 2C.2  
YFP* 
type IV spacer 
Y4.2  
CFP C4.1  
spacer type IV 
YFP* 4Y.1  
Cerulean 4Cer.1  
CFP 4C.6  
spacer
(3)
 all above spacer 2.6; 4.3; 5.4; 6.2  
Table 5: Constructs cloned using Invitrogen Multisite Gateway Technology 
The published constructs are YFP-AC5 (clone Y5.9) and sREACh-AC5 (clone D5.2). The final 
constructs were not completely sequenced, but all intermediate constructs were verified by 
sequencing. (1) YFP*: eYFP(F46L/L68V) cloned by J. P. Vilardaga. (2) CFP: enhanced CFP 
(eCFP) was used in this study. (3) ACs flanked by spacers were generated to obtain “wild-type-
like” ACs that have the same additional linker on the C-terminus like the other constructs and 
are in the same vector backbone. However, these constructs were not used in these studies. 
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Figure 8: Representative plasmid maps 
The maps show the plasmid of YFP-AC5 (left) and AC5-YFP (right). They are representative 
for the fluorescently labelled AC-constructs listed in Table 5. 
In addition to the plasmids mentioned above, AC5-wt in pcDNA3 was cloned. This 
construct was obtained from the YFP-AC5-construct provided by Carmen W. Dessauer 
(University of Texas, Houston) and used for control purposes. 
3.2 Expression of fluorescent AC-constructs in HEK293T cells 
HEK293T cells can be easily transfected with the constructs. Even though transient 
overexpression of ACs is easy and obviously well tolerated by HEK293T cells, the 
constructs tend to predominantly localise to intracellular compartments – most likely 
membranes of the endoplasmic reticulum or Golgi apparatus – especially in cells 
expressing large amounts of protein. Optimisation of the transfection conditions 
enhanced cell membrane localisation of YFP-AC5. Cells that expressed lower amounts 
of tagged protein showed better membrane staining than bright cells expressing large 
quantities of YFP-AC5 (Figures 9A upper panel and 9B). Epifluorescence images are, 
however, not optimal to judge membrane localisation, especially if the expression is 
weak. Therefore, confocal images were acquired, which revealed that the construct 
localised well to the cell membrane (Figure 9C). 
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Figure 9: Subcellular localisation of YFP-AC5 and immunological detection of ACs 
A to C): HEK293T cells were transiently transfected with YFP-AC5 and Gαi1-CFP, as well as 
unlabelled α2A-AR and Gβ1γ2-subunits. All scale-bars represent 20 µm. A) Cells were fixated, 
treated for immunofluorescence staining against ACs as detailed in the methods section and 
images were acquired with an epifluorescence microscope. YFP-AC5 was excited at 
480 ± 20 nm and fluorescence recorded at 527 ± 15 nm (upper panel). The primary antibody 
against type V and VI ACs (SC-590) was detected using a red DyLight 650-conjugated 
secondary antibody (lower panel). This fluorophore was excited at 620 ± 30 nm and emission 
recorded at 700 ± 37 nm. SC-590 produced a uniform staining of all cells, regardless of the 
transfection state. B) Magnifications of the respective regions in A. Cells strongly 
overexpressing YFP-AC5 showed major intracellular fluorescence (1), whereas weakly 
expressing cells showed better membrane localisation of YFP-AC5 (2). The contrast of 
magnification (2) was enhanced by reduction of the input range to 75 %. C) This confocal 
image, acquired from non-fixated cells, shows the membrane localisation of YFP-AC5 in a 
weakly expressing cell. YFP-fluorescence was excited using the 514 nm line of an Ar-laser. D) 
Western-Blot using the anti-AC5/6 antibody SC-590. Endogenous AC5 should be represented 
by a band at about 130 kDa, YFP-tagged AC5 at 160 kDa. For control purposes HEK293T cells 
were either not transfected at all (untransf.) or transfected with empty vector (pcDNA3). The 
other conditions contained YFP-AC5 or AC5-wt, respectively, cotransfected with Gαi1-CFP, 
α2A-AR and Gβγ. 
There is consensus in the scientific field about the poor specificity of antibodies against 
ACs (Gottle et al., J. Pharmacol. Exp. Ther. 2009). It was therefore not possible to 
determine the expression level of endogenous or transfected ACs or their subcellular 
distribution by means of immunofluorescence. In immunofluorescence experiments the 
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antibody produced a uniform staining in all cells, regardless of their transfection state or 
the cellular distribution of YFP-AC5 (Figure 9A lower panel). In Western-Blot 
experiments it produced a uniform prominent band at about 43 to 45 kDa, independent 
of the transfection of the cells (Figure 9D). This is only about 1/3 of the expected mass 
of AC5 (about 130 kDA, YFP-AC5 would be even heavier), but a very close match for 
the mass of actin. As no specific information about the subcellular distribution of 
endogenous ACs could be obtained from these experiments, it cannot be decided, 
whether YFP-labelled AC5 shows wild-type-like membrane targeting or not.  
Among the generated constructs YFP-AC5 (Y5.9 in the author’s lab journal) was the 
brightest and the one that localised best to the cell membrane. It was therefore further 
characterised and used in the FRET-experiments. 
3.3 Characterisation of the newly generated YFP-AC5 
Functional characterisation of fluorescent protein-labelled constructs is crucial. The 
newly cloned construct YFP-AC5 was compared to unlabelled AC5-wt with regard to 
forskolin activation, activation by Gs-proteins and regulation by Gi-proteins. Parts of 
these experiments were performed in collaboration with the workgroup of Dr. Frank 
Wunder at Bayer Healthcare Research Center in Wuppertal (Germany).  
Using the bioluminescence-based cAMP-assays of Bayer Healthcare (Wunder et al., 
Mol. Pharmacol. 2008) the generation of cAMP was compared in CHO cells transfected 
with either AC5-wt, YFP-AC5 or mYFP for control purposes. Application of 10 µM 
forskolin or more resulted in a robust generation of cAMP in all three conditions, 
mainly due to endogenous ACs. Notably, cells transfected with either AC5-wt or 
YFP-AC5 showed elevated cAMP generation at forskolin concentrations between 
30 nM and 3 µM. This resulted in biphasic concentration-response curves, suggesting 
the expression of additional, functional ACs apart from those endogenously present 
(Figure 10). 
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Figure 10: cAMP generation of AC5-constructs upon stimulation with forskolin 
Average concentration-response curves to compare the forskolin-induced cAMP generation of 
AC5-wt and YFP-AC5 (mean ± S.E.M., n=5). The conditions were measured in parallel and 
normalised to the bioluminescence signal of YFP-AC5. cAMP generation was assessed using a 
bioluminescence-based cAMP reporter system in CHO cells. This assay reports changes in 
cellular [cAMP] through the cAMP-dependent activity of CNG-channels, which finally results 
in bioluminescence. Please refer to the methods section for further details. Application of 
forskolin (FSK) led to robust cAMP generation. 30 nM to 3 µM FSK resulted in biphasic 
concentration-responses in cells transfected with either YFP-AC5 or AC5-wt, as observed by 
the higher bioluminescence in this concentration range in comparison to control cells transfected 
with membrane-associated YFP (mYFP). 
As forskolin is able to penetrate through the cell membrane and activate any AC, 
regardless of its localisation or nature (endogenous or transfected), a protocol to more 
selectively stimulate only transfected cells was worked out. The CHO cells used in the 
bioluminescence-assay don’t express endogenous β2-adrenergic receptors (β2-AR). This 
receptor was therefore cotransfected together with the constructs mentioned above and 
cells were stimulated with isoprenaline (Iso). This experimental setup resulted in 
superimposable concentration-response curves for AC5-wt and YFP-AC5. 
Overexpression of the AC-constructs significantly increased the cAMP generation over 
control cells (Figure 11). These results verified wild-type-like Gs-signalling competence 
of the newly generated YFP-AC5. 
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Figure 11: cAMP generation of AC5-constructs mediated by β2-AR stimulation 
Average concentration-response curves to compare Gs-signalling competence of AC5-wt and 
YFP-AC5 (mean ± S.E.M., n=5) using the same cAMP reporter system as in Figure 10. CHO 
cells were transfected with β2-AR and the indicated constructs. The conditions were measured in 
parallel and normalised to the maximum bioluminescence signal of the YFP-AC5 transfection. 
Stimulation of the β2-AR led to a stronger cAMP generation in cells that were transfected with 
the AC-constructs, than control cells (mYFP). Statistics were obtained with ANOVA and 
Dunnet’s multiple comparison test (**/## p<0.01; ***/### p<0.001). Significant differences 
between mYFP and YFP-AC5 or mYFP and AC5-wt are represented by asterisks (*) or number 
signs (#), respectively. 
So far cAMP-assays are limited in their detection of Gi-mediated changes of the second 
messenger. Therefore, the Gi-dependent regulation of YFP-AC5 could not be 
characterised using the CNG-channel-based bioluminescent assays. The FRET-based 
cAMP sensor Epac1-camps provides an alternative way to measure cAMP production in 
living cells. A protocol was established to measure Gs- and Gi-protein regulation of 
AC5. The expression of YFP-AC5 together with Epac1-camps would interfere with the 
sensor’s signal/noise-ratio, though. To circumvent this impairment sREACh (non-
fluorescent variant of YFP, “dark YFP”) (Murakoshi et al., Brain Cell Biol. 2008) was 
cloned to the N-terminus of AC5, thereby generating a non-fluorescent construct of 
similar build as YFP-AC5. This construct was characterised in comparison to AC5-wt 
using the Epac1-camps and no difference between them was observed (see section 
3.5.2.2.1 and Figure 29). From these experiments it was concluded, that sREACh-AC5 
and likewise YFP-AC5 is under proper wt-like dual control of Gs- and Gi-proteins. The 
according experiments were performed in analogy to further functional studies that are 
presented later. 
Having verified functionality and G-protein signalling competence of YFP-AC5 the 
receptor-induced FRET with G-protein subunits was investigated. 
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3.4 FRET-based detection of the interaction between YFP-AC5 and 
partners of the GPCR, G-protein signalling pathway 
To investigate the interaction between the different G-protein subunits and AC5 a 
heterologous overexpression system was used. HEK293T cells were transiently 
transfected as described in the methods section. Unless stated otherwise, the indicated 
labelled partners were transfected together with the remaining unlabelled G-protein 
subunits and the according receptor. In most experiments YFP-AC5 was used as the 
FRET-acceptor. However, where CFP-labelled partner proteins were not available, Cer-
labelled AC5 was used. This is indicated in the individual figures. 
3.4.1 Basal interaction between the labelled partners 
It has been reported that ACs and G-proteins interact under non-stimulated conditions 
and form signalling complexes (Rebois et al., Cell. Signal. 2012). Donor fluorescence 
recovery after acceptor photobleaching is a standard method to determine basal, non-
stimulated interaction between FRET-pairs. It was used to investigate potential basal 
interaction between YFP-AC5 and CFP-labelled G-protein subunits. The difference in 
donor (CFP) fluorescence before and after bleaching of the acceptor (YFP) for 
6 minutes was analysed. An increase in donor fluorescence reveals basal FRET between 
the fluorophores. The Gαi1/Gβ1γ2-FRET assay (see section 3.5 for further details) 
provided a positive control, as the Gαi1-YFP/Gγ2-CFP-pair shows FRET under non-
stimulated conditions. Transfections containing CD86-YFP (Dorsch et al., Nat. Methods 
2009), a T-cell receptor that does not interact with G-proteins, was used as a negative 
control. Additionally an acceptor-free transfection with AC5-wt allowed to control for 
donor-bleaching during the whole experimental procedure. The acceptor-free condition 
shows a loss in donor-fluorescence of about 3 % (-2.7 ± 1.4 %; n=12). A minor increase 
in donor-fluorescence of 1.4 ± 1.1 % (n=12) could be observed for the 
Gαs-CFP/YFP-AC5-pair, which was not significantly different from the increase 
observed for the positive control, i.e. the Gαi1/Gβ1γ2-FRET (5.1 ± 1.0 %; n=25). 
Furthermore, the according control condition (Gαs-CFP/CD86-CFP) showed a similar 
increase (1.3 ± 2.0 %; n=4). In contrast to this, all other tested pairings showed on 
average a decrease in donor fluorescence. Statistic comparison against Gαi1/Gβ1γ2-
FRET revealed significant differences of those conditions as shown in Figure 12. 
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Figure 12: Donor fluorescence recovery after acceptor photobleaching 
Depicted is the relative change of donor (CFP) fluorescence after 6 minutes of acceptor (YFP) 
photobleaching (mean ± S.E.M., n≥9). HEK cells were transfected with the indicated labelled 
proteins together with unlabelled G-protein subunits and receptors. The Gαi1-YFP/Gβ1γ2-CFP 
pair shows FRET under non-stimulated conditions and was used as a positive control (left bar). 
The CD86 T-cell receptor does not interact with G-proteins and was used in combination with 
Gαi1 as a negative control (second bar from right). The transfection with AC5-wt (right bar) did 
not contain any YFP-labelled construct and was used to monitor bleaching of CFP during the 
experiments. Statistics were obtained using ANOVA and Dunnett’s multiple comparison test 
against the negative control condition Gαi1-CFP/CD86-YFP (** p≤ 0.01, not significant 
differences are not indicated). 
The results from the bleaching experiments did not hint at a basal interaction between 
AC5 and G-protein subunits. 
3.4.2 Interaction between AC5 and a GPCR 
For AC2 a complex of the AC with its regulating Gi-protein and the according receptor 
has been proposed previously (Rebois et al., Cell. Signal. 2012). The possibility of a 
similar signalling complex between AC5 and the α2A-AR was therefore investigated by 
means of Förster Resonance Energy Transfer (FRET). The FRET donor, in this case 
Cer-AC5, because the receptor was labelled with YFP, was excited at 430 ± 12 nm and 
the fluorescence of Cerulean (Cer) and YFP was recorded simultaneously at 
488 ± 20 nm and 534 ± 10 nm, respectively. The individual fluorescences of both 
fluorophores, FCFP and FYFP, respectively, were corrected for background fluorescence 
and spectral crosstalk as detailed in the methods section. Finally, 
    
    
 was calculated 
and is presented in most following figures. This ratio is also referred to as “FRET-
ratio”. The cells were continuously superfused with buffer or agonist-containing buffer, 
during the experiments. As shown in Figure 13 no FRET-signal was observed between 
α2A-AR-YFP and Cer-AC5. 
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Figure 13: No FRET between α2A-AR and AC5 
HEK293T cells were transiently transfected with Cer-AC5, α2A-AR-YFP and unlabelled 
Gi1-protein subunits. Cerulean (Cer) was excited at 430 ± 12 nm and the fluorescence of Cer 
and YFP simultaneously recorded at 488 ± 20 nm (FCFP) and 534 ± 10 nm (FYFP), respectively. 
The FRET-ratio derived from the corrected individual fluorescences (please refer to the methods 
section for further) is presented in this figure. Cells were continuously superfused with buffer or 
norepinephrine (NE)-containing buffer (indicated by the line). No FRET was observed between 
Cer-AC5 and the YFP-labelled α2A-AR. This recording is representative for 6 experiments. 
3.4.3 Interaction between AC5 and G-proteins 
Generally, the observed agonist-dependent changes between YFP-AC5 and the labelled 
Gs- and Gi-protein subunits where rather small in amplitude (Figure 14). The agonist 
induced FRET-change between CFP-labelled Gα-subunits and YFP-AC5 resulted in 
slightly larger amplitudes, than FRET-changes between Cer-Gβ1γ2 and YFP-AC5: 
ΔFYFP/FCFP of 0.021 ± 0.005 (n=7) and 0.012 ± 0.002 (n=7), respectively (values for 
Gs-protein). 
 
Figure 14: FRET-change between YFP-AC5 and G-protein subunits upon stimulation 
with agonist 
The bar graph shows the averaged increase in FRET upon agonist stimulation (mean ± S.E.M., 
n≥6). HEK293T cells were transiently transfected with YFP-AC5, labelled and unlabelled 
G-protein subunits as indicated and β2-AR (for Gs-proteins) or α2A-AR (for Gi1-proteins). Cells 
were stimulated with either 1 µM isoprenaline (Gs-protein) or 10 µM norepinephrine 
(Gi-proteins) and the change in FRET between baseline and agonist-induced FRET-signal was 
measured. 
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The small amplitudes might be explained by a distance between the fluorophores larger 
than the Förster radius. Combined with the low expression level of the labelled partners 
this resulted in a low signal/noise-ratio. Nevertheless, the assays were reliable and 
allowed reproducible induction of agonist-dependent changes in FRET between 
YFP-AC5 and G-protein subunits, which are described in more detail in the following 
chapters. 
3.4.3.1 Interaction between AC5 and Gαs-subunits 
To make sure the small amplitude were not due to unfavourable expression of the 
FRET-partners, the expression ratio between Gαs-CFP and YFP-AC5 was analysed 
analogous to control experiments for the FRET between Gαi1 and AC5 (compare section 
3.5.1.1). The expression ratio between CFP and YFP was 0.57 ± 0.07 (mean ± S.E.M., 
n=12) ranging from 0.2 to 1, i.e. 5-fold overexpression of YFP-AC5 over Gαs-CFP to 
equal expression, respectively. An excess of FRET-acceptor is ideal, because in this 
condition every donor has an acceptor to interact with. 
Upon stimulation of the cotransfected β2-adrenergic receptor (β2-AR) the FRET 
between Gαs-CFP and YFP-AC5 increased. After a transient peak that reached about 
150 % of the final plateau value, the reaction plateaued after 5-6 seconds (Figure 15). 
This transient peak occurred at concentrations as low as 10 nM isoprenaline (Figure 
15C). It could also be induced by another receptor (A2A-adenosin receptor). Switching 
the fluorophores on Gαs and AC5 did not affect the transient peak either (Figure 15E). It 
was not observed at agonist concentrations below 10 nM Iso. However, these conditions 
resulted in a slow development of the FRET-signal and might have thereby blunted the 
development of this transient peak. 
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Figure 15: Agonist-dependent FRET between AC5 and Gαs is characterised by a transient 
peak 
Depicted are representative single cell FRET recordings for HEK293T cells transiently 
transfected with the labelled constructs as indicated by the icons (Y: YFP, e.g. YFP-AC5; 
C: CFP, e.g. Gαs-CFP) together with the indicated unlabelled receptor and Gβ1γ2-subunits. Cells 
were continuously superfused with buffer or agonist-containing buffer. Superfusion with 
agonist-containing buffer is indicated by the line in this and the following figures. The 
fluorescence of CFP was excited at 430 ± 12 nm and the fluorescence of CFP and YFP (FCFP 
and FYFP) was simultaneously recorded at 488 ± 20 nm and 534 ± 10 nm, respectively. The 
sampling rate was 2 Hz, if not indicated otherwise. The individual fluorescences (A, lower 
panel) were corrected for background fluorescence and spectral crosstalk (please refer to the 
methods section for further details). The FRET-ratio (FYFP/FCFP) was calculated and is depicted 
in the upper panel of A. A) Upon stimulation with isoprenaline (Iso, as indicated) FYFP 
increased, while FCFP was decreased (lower panel). This indicated an increase in FRET between 
Gαs-CFP and YFP-AC5, which is better visualised by the increase in the ratio trace (upper 
panel). Please note the characteristic transient peak before the plateau in the agonist-mediated 
FRET-increase. B) This sample recording (acquired at 33 Hz) shows the onset-kinetics of the 
reaction for the same conditions as used in A. Recordings like this were used to calculate the 
kinetics summarised in Figure 17C. The transient peak also occurs at agonist concentrations as 
low as 10 nM Iso (C, equal transfection as in A), when a different receptor (A2A-adenosine 
receptor) is cotransfected and stimulated (D) or after exchange of the fluorophores of AC5 and 
Gαs (E, this is a 33 Hz recording). 
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The onset of the FRET-change upon agonist stimulation was fast, the t0.5 to the 
maximum of the peak being in the sub-second range (0.26 s, see Figures 15 and 17) and 
similar to the activation-kinetics of the Gs-protein as published previously (Hein et al., 
J. Biol. Chem. 2006). The half-life for the transition from peak to plateau was about 
0.9 s (λ=0.77 ± 0.09 s-1, n=7). 
To verify the specificity of the observed FRET-signal between Gαs and AC5 a negative 
control was looked for. Although Gq-proteins might be cross-talking to the cAMP 
pathway (Sassone-Corsi, Cold Spring Harb. Perspect. Biol. 2012), ACs are not 
considered to be a target for Gq-protein signalling themselves and therefore no FRET-
signal is expected to develop.  
 
Figure 16: No FRET between Gαq-CFP and YFP-AC5 
HEK293T cells were transiently transfected with Gαq-CFP, YFP-AC5, unlabelled 
M3-acetylcholine receptor and Gβ1γ2. The experiments where performed as described in Figure 
15. Application of acetylcholine (ACh, as indicated) does not result in FRET between AC5 and 
Gαq. This sample trace is representative for 4 experiments. 
The absence of FRET between Gαq and AC5 confirmed the reliability of the Gαs/AC5-
FRET-signal. 
3.4.3.2 Interaction between AC5 and Gβγ-subunits 
Gβγ-subunits bind to the N-terminus of AC5 and are necessary for Gαs-mediated 
activation of the enzyme. Using Gβ1-Cer as the FRET-donor for YFP-AC5 an agonist-
dependent FRET-increase was observed. The kinetics of this FRET-increase were 
indistinguishable from those of the Gαs/AC5-FRET (Figure 17). 
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Figure 17: Agonist-dependent FRET between AC5 and Gβγ-subunits 
HEK293T cells were transiently transfected with YFP-AC5, Cer-Gβ1, Gγ2 and Gαs or Gαi1, 
respectively. β2-AR or α2A-AR were cotransfected to stimulate Gs- or Gi-proteins, respectively. 
Experiments were performed in analogy to those depicted in Figure 15. A) Upon stimulation of 
the β2-AR with isoprenaline (Iso, as indicated) FRET develops between AC5 and Gβγ-subunits 
derived from Gs-proteins. B) Gi-protein-derived Gβγ-subunits also showed FRET with AC5 
upon stimulation of the α2A-AR with norepinephrine (NE). C) The bar graph depicts the average 
onset rate constant of the FRET-increase between YFP-AC5 and the indicated labelled partners 
upon agonist stimulation (mean ± S.E.M., n≥6). All conditions showed similar kinetics, the t0.5 
values ranging from 0.367 s (Gαi1, Cer-Gβ1γ2) to 0.255 s (Gαs-CFP, Gβ1γ2, measured to 
maximum of the peak). 
The similar onset of the FRET-change between AC5 and the different Gs-protein 
subunits is in line with reports of their simultaneous binding to the AC’s N-terminus 
(Sadana et al., Mol. Pharmacol. 2009). Interestingly, the characteristic peak in the onset 
of FRET between Gαs and AC5 was not observed in FRET-experiments between AC5 
and Gβ1γ2-subunits. This points at additional conformational changes that might occur 
between AC5 and Gαs upon activation. 
Signalling complexes including Gi-coupled receptors and AC5 have been reported 
(Rebois et al., Cell. Signal. 2012) and it can easily be imagined that Gi1-proteins are 
participating in those complexes. As depicted in Figure 17 Gi-derived Gβ1γ2-subunits 
also change FRET with AC5 in an agonist-dependent manner. The according FRET-
signal closely resembles that of Gs-derived Gβγ-subunits. This indicates that Gi-derived 
Gβγ-subunits interact with AC5 in a similar manner as those derived from Gs-proteins. 
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Having observed not only FRET-changes between Gs-derived Gβγ and AC5, but also 
AC5 and Gi-derived Gβγ, the FRET between AC5 and Gαi1 was investigated next. 
3.4.3.3 Interaction between AC5 and Gαi1-subunits 
Upon agonist stimulation of the cotransfected α2A-AR an increase in FRET between 
YFP-AC5 and Gαi1-CFP was observed. This increase closely resembled the FRET-
increase observed with Gβ1γ2 and AC5, it did not show the transient peak observed in 
the Gαs/AC5 FRET (Figure 18). In the following, the FRET-assay to resolve the 
interaction between Gαi1-CFP and YFP-AC5 is termed Gαi/AC5-FRET assay. The 
different shape of the FRET-signal might be due to the different binding sites of the 
Gα-subunits in AC5. But consistently at higher (saturating) concentrations, the FRET-
traces showed a transient increase in the FRET-ratio upon agonist washout. To make 
sure, that this transient was not a unique property of the cotransfected α2A-AR, the 
receptor was exchanged for the type 2 muscarinic acetylcholine receptor (M2-AChR). 
Obviously the observed transient is not dependent on the receptor, as it occurred in 
these experiments as well (compare representative samples in Figure 18). 
 
Figure 18: Agonist-dependent FRET between Gαi1 and AC5 
HEK cells were transfected with YFP-AC5, Gαi1-CFP, α2A-AR and Gβ1γ2. A) The representative 
single-cell FRET-recording shows the FRET-change induced by agonist stimulation of the 
receptor by norepinephrine (NE, as indicated). Upon agonist washout a transient increase in the 
FRET-ratio was observed, which was also represented by the opposing course of the individual 
fluorescence traces. B) The transient occurred also in cells transfected with the M2-AChR, 
instead of the α2A-AR. This recording was corrected for bleaching. 
Agonist-mediated changes in FRET were small in the Gαi/AC5-FRET assay and of 
similar amplitude as those of the Gαs/AC5-FRET. The specificity of this signal was 
controlled by checking for unspecific FRET between Gi1-proteins and non-interacting 
membrane proteins like CD86 T-cell receptor. No agonist-dependent FRET-change 
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could be elicited between Gαi1-CFP and CD86-YFP, thereby verifying the changes 
observed in the Gαi/AC5-FRET (Figure 19). 
 
Figure 19: Agonist-induced FRET-change between Gαi1 and AC5 
The Gαi/AC5-FRET pair showed a robust signal, which was not observed in the control 
condition. Depicted is the average agonist-dependent FRET-increase (mean ± S.E.M., n≥8). 
Statistics were obtained by a t-Test (*** p≤0.001). 
In the initial Gαi/AC5-experiments high agonist concentrations were applied, frequently 
1 µM NE and higher. These concentrations were applied in order to induce saturating 
conditions with the highest possible amplitude. As revealed by later experiments, this 
was not the optimal approach. 
 
Figure 20: High agonist concentrations reduce the amplitude of the FRET-change between 
Gαi1-CFP and YFP-AC5 
HEK cells were transiently transfected with the plasmids for the Gαi/AC5-FRET assay and 
sequentially stimulated with increasing concentrations of NE (as indicated). Concentrations of 
10 nM NE and more reliably showed the transient increase in FRET upon agonist washout. 
While the transient increase reached about the same level after each stimulation (dark grey line), 
the actual agonist-induced FRET-change was reduced with each increasing concentration above 
10 nM NE (light grey line). This recording was corrected for bleaching and smoothened using 
Savitzky-Golay algorism. The X-axis was interrupted as indicated by the dotted lines. 
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As shown in the representative recording in Figure 20 the transient could be observed 
consistently after the application of 10 nM NE or more. Furthermore, increasing agonist 
concentrations reduced the amplitude of the actual agonist-induced FRET-change, while 
the overall amplitude (i.e. agonist-induced FRET-signal plus transient) was not affected. 
This observation might hint at self-inhibitory effects of the signalling pathway, possibly 
mediated through the α2A-AR as described previously (Hommers et al., J. Biol. Chem. 
2010). 
The application of high agonist concentrations also resulted in another phenotype, 
especially in the presence of higher receptor expression as used in these initial 
experiments. However, the following has not been verified at lower amounts of 
transfected receptor. Upon stimulation with 10 µM NE and subsequent agonist 
withdrawal the transient occurs as expected, but the recovery is incomplete. A second 
stimulation no longer leads to the expected agonist-dependent FRET-increase 
(Figure 21). Nevertheless, the transient is elicited again upon agonist washout. Even a 
very brief application of ~1 s is sufficient to stimulate the transient. If agonist is applied 
again within the transient of a previous stimulation, the FRET-ratio drops back to the 
amplitude of the initial agonist-induced stimulation and recovered to the transient’s 
maximum level after withdrawal. 
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Figure 21: Incomplete recovery of the FRET-signal between Gαi1-CFP and YFP-AC5 after 
high concentrations of agonist 
HEK cells were transfected with the Gαi/AC5-FRET assay and subjected to single cell FRET-
recording. During the recording the cell was repeatedly stimulated with 10 µM NE as indicated 
by the black lines. The upper panel shows the complete recording, while the lower panel shows 
magnifications of the individual agonist applications. The first stimulation (S1) resulted in an 
agonist-dependent FRET-increase between Gαi1-CFP and YFP-AC5 (dotted line). It further 
elicited the transient increase upon agonist washout. The FRET-ratio did not recover to baseline 
again, but to the level of the agonist-induced amplitude of the first stimulation. The second 
stimulation (S2) showed no agonist-dependent amplitude, but the transient FRET-increase 
occurred. This transient was also elicited by an about 1 s long stimulation (S3/4). Agonist 
application within the transient’s maximum resulted in a decrease of the FRET-ratio back to the 
level of the first agonist-induced amplitude. The recording was corrected for bleaching. 
These observations raised the question, whether the offset-kinetics of the Gαi/AC5-
FRET were different, especially slower, than that of G-protein deactivation. This was 
especially interesting in the light of differences in the sensitivity towards agonist that 
were observed. As this is part of the major findings of this study, it was assigned an 
individual section below (section 3.5). 
As Go-proteins belong to the same major family of G-proteins, the agonist-dependent 
FRET with AC5 was tested as well. Even though they have been reported to regulate 
AC2 (Nasman et al., J. Neurochem. 2002) they had also been reported to not interact 
with AC5 (Xie et al., Sci. Signal. 2012). This allowed for the verification of the FRET-
signal between Gαi1 and AC5 using a negative control from the same G-protein family. 
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Figure 22: No FRET between Gαo and AC5 
HEK cells were transfected with Gαo-YFP, Cer-AC5, M2-acetylcholine receptor and Gβ1γ2. 
Activation of the receptor by acetylcholine (ACh) does not result in FRET between the two 
proteins. This trace is representative for 3 experiments. 
As shown in Figure 22 no agonist-dependent change in FRET between Gαo-YFP and 
Cer-AC5 could be elicited. This verified the previous reports and corroborated the 
Gαi/AC5-observations. 
Some preliminary experiments between Gαi1 and AC5 hinted at a high sensitivity of the 
interaction between the two partners. It seemed that this interaction was even more 
sensitive, than expected by the activation of the Gi-protein. Therefore, the Gαi/AC5-
FRET and the Gi1-protein activity, also assessed by FRET, were compared directly 
under similar experimental conditions. 
3.5 Sensitivity of agonist-mediated Gi1-protein activation and Gαi1/AC5-
interaction 
Our lab has previously developed and published an assay to investigate the activation of 
the Gi1-protein by means of FRET (Bünemann et al., Proc. Natl. Acad. Sci. U. S. A. 
2003). This assay resolves agonist-dependent changes in the conformation of the 
Gi1-protein. Upon receptor stimulation FRET increases between Gαi1-YFP and 
Gβγ-Cer. This argues in favour of subunit rearrangement, rather than subunit 
dissociation, as the latter would be expected to induce a loss in FRET. Figure 23 shows 
a representative recording of this assay. 
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Figure 23: Agonist-dependent FRET-change in the Gi1-protein 
This representative single cell recording shows the agonist-dependent FRET-changes between 
Gαi1-YFP and Cer-Gβ1. Gγ2 and α2A-AR were cotransfected. Stimulation of the α2A-AR with 
norepinephrine (NE) resulted in an increase in FRET between the G-protein subunits as 
represented by the increase in the FRET-ratio (upper panel) and the opposing movement of the 
individual fluorescence traces (lower panel). The signal was reversible upon agonist washout. 
The assay was adapted to the experimental conditions of the Gαi/AC5-FRET assay to 
directly compare them. The assay to resolve conformational changes in the G-protein 
will be referred to as Gαi/Gβγ-FRET, hereafter. 
3.5.1 Direct comparison of the sensitivity of Gi1-protein activation and 
Gαi1/AC5-interaction towards agonist-mediated receptor stimulation 
To investigate the sensitivity of Gαi/AC5-FRET and Gi1-protein activation 
concentration-response curves were recorded for both conditions. HEK293T cells, 
transiently transfected with either the Gαi/AC5- or Gαi/Gβγ-FRET assay, were 
superfused with increasing concentrations of agonist. To obtain a control value for each 
cell the agonist was washed off after the highest concentration and the saturating 
concentration was applied again. To avoid incomplete recovery in the Gαi/AC5-FRET 
after application of high agonist concentrations (see Figure 21 and section 3.6.1 for 
details) the agonist washout was performed after application of 10 nM NE (Figure 
24A). Preliminary experiments revealed this to be a usually saturating concentration. 
Therefore, not all of the higher concentrations had to be tested. Please refer to the 
methods section for a detailed description of how the amplitudes were measured and 
normalised. 
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Figure 24: Different sensitivity of Gi1-protein activation and Gαi/AC5-FRET 
A) This representative single-cell FRET-recording of HEK cells transfected with the Gαi/AC5-
FRET assay depicts the dependence of the FRET-signal on the agonist-concentration. Agonist 
was washed out after the application of 10 nM NE to record the transient increase in the FRET-
ratio. 1 µM NE was applied for comparison after the FRET-change had recovered to baseline. 
This recording was corrected for bleaching and smoothened using Savitzky-Golay algorism. 
The transient’s maximum after 10 nM NE was set as the amplitude for 10 nM NE in order to 
avoid contribution of the unknown inhibitory component. The other amplitudes were 
normalised to this value to obtain concentration-response curves. B) Representative 
concentration-response curves from single-cell recordings for NE-evoked changes in Gαi/AC5- 
and Gαi/Gβγ-FRET (upper panel). RGS4 was cotransfected as indicated. The lower panel shows 
the average EC50-values (mean ± S.E.M., n≥11). Statistics were obtained with ANOVA and 
Bonferroni post-hoc test (*** p<0.001). 
As shown in Figure 24B Gi1-protein activation has an EC50 of 3.2 nM norepinephrine 
(NE). Contrastingly, the EC50 for the FRET-changes between Gαi1 and AC5 is indeed 
shifted leftwards by one order of magnitude to 0.3 nM NE. If RGS4 was coexpressed 
with either assay, the EC50-values tended to be increased. This effect was not 
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statistically significant, though. The effect of RGS4 was tested and is presented in this 
figure, because of a possible involvement of the interaction dynamics in the sensitivity 
shift, which are presented later in section 3.6. 
Certain experimental conditions can alter the apparent sensitivity of the assays. 
Confounding conditions are receptor-overexpression in the AC5-containing assay or 
excess of the FRET-donor, i.e. Gαi1-CFP. In order to rule out these influences, the 
receptor expression was analysed as well as the relative expression of the FRET-
partners. 
3.5.1.1 Verification of equal expression levels of the α2A-AR 
Higher expression levels of the receptor can result in seemingly higher agonist 
sensitivity of an assay as reported previously (Bunemann et al., J. Biol. Chem. 2001). 
Western-Blots against the HA-tag on the receptor N-terminus were performed to 
investigate the expression levels. Both assays, Gαi/Gβγ-FRET and Gαi/AC5-FRET, 
showed about equal expression of the receptor with a tendency towards a little less 
expression in the Gαi/AC5-assay (Figure 25). Quantification of the Western-Blot 
resulted in an average expression ratio of 75.6 ± 9.9 % for the Gαi1/AC5-condition in 
comparison to the Gαi/Gβγ-assay (mean with S.E.M., n=3). Therefore, different 
receptor levels could most likely not account for the difference in sensitivity. 
 
Figure 25: Western-Blot analysis of the expression of HA-tagged α2A-AR 
Three independent transfections (black brackets) were analysed for α2A-AR expression. Cells 
were transfected with components of the Gαi/Gβγ-FRET (Gi-FRET) or Gαi/AC5-FRET assay 
(Gαi/AC). Untransfected cells (untransf.) and cells only transfected with empty pcDNA3 (mock) 
were used as negative controls. Cells only transfected with α2A-AR (control) were used as a 
positive control. Whole-cell lysates were obtained as detailed in the methods section. The 
HA-tag on the receptor was detected by a monoclonal antibody (HA.11 Clone 16B12, mouse, 
Covance). After stripping of the membrane actin was detected using a monoclonal antibody 
(Anti-actin clone C4, mouse, Merck Millipore). 
The RGS4-construct used in these assays was also tagged with HA. Accordingly, its 
expression was also analysed by means of Western-Blotting, but the protein was not 
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detected. Either the expression of HA-tagged RGS4 was too low for proper detection by 
the used antibodies, or the protocol to obtain the cell-lysates was inadequate for the 
analysis of cytosolic proteins. 
3.5.1.2 Determination of the relative expression level of the FRET- partners 
Apart from differences in receptor levels, the relative expression of the FRET-partners 
could also be a reason for the high sensitivity observed in the Gαi/AC5-assay in 
comparison to the Gαi/Gβγ-FRET. Strong overexpression of the FRET-donor 
(Gαi1-CFP) over YFP-AC5 could theoretically lead to the saturation of the FRET-
acceptor already at a small portion of activated G-proteins and therefore result in 
seemingly higher sensitivity of the assay. As mentioned in section 3.2, substantial 
amounts of overexpressed AC5 tended to accumulate inside the cell. YFP-AC5, 
localised in such compartments, did not interact with membrane-bound G-protein 
subunits. Conclusively, the analysis of whole-cell lysates or membrane preparations 
from whole cells would result in expression levels not reflecting the actual situation at 
the cell membrane. To determine the relative expression levels of Gαi1-CFP and 
YFP-AC5 the fluorescence intensity of CFP and YFP was analysed at the cell 
membrane and compared to a reference construct. The reference construct 
YFP-β2-AR-CFP (Dorsch et al., Nat. Methods 2009) expresses YFP and CFP with a 
stoichiometry of 1:1. Please refer to the methods section for a detailed description of the 
measurement and data analysis. As shown in Figure 26, both FRET-partners are about 
equally expressed at the membrane. 
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Figure 26: Relative expression of Gαi/AC5-FRET-partners at the cell membrane 
The fluorescence of the reference construct YFP-β2-AR-CFP (Dorsch et al., Nat. Methods 2009) 
was analysed by individual excitation of both fluorophores and the fluorescence ratio for this 
1:1-stoichiometry of CFP and YFP was calculated. Furthermore, the fluorescence intensity of 
Gαi1-CFP or YFP-AC5 was measured individually in cells transfected with the Gαi/AC5-FRET 
assay and related to the fluorescence ratio of the control construct. Please refer to the methods 
and results sections for details on measurement and calculations. Depicted is the average ratio 
(left column) of CFP/YFP (mean ± S.E.M., n=15), which represents the expression of Gαi1 in 
relation to AC5. The data points depicted in the right part represent the individual values 
obtained in these experiments 
On average, Gαi1-CFP and YFP-AC5 were expressed equally, the ratio being 
0.92 ± 0.13 (mean ± S.E.M., n=15). The individual expression ratio ranged from 0.3 to 
2 (i.e. 3-fold overexpression of AC5 over Gαi1 or 2-fold excess of Gαi1 over AC5, 
respectively). 
Using these methods and the correction factor obtained from the reference construct, the 
datasets of the kinetics and concentration-response curve experiments were analysed 
retrospectively. In the kinetics experiments the expression ratio of Gαi1-CFP over 
YFP-AC5 was 0.96 ± 0.14 (mean ± S.E.M., n=12; ranging from 0.3 to 1.8). The 
concentration-response experiments show an expression-ratio of 1.17 ± 0.32 
(mean ± S.E.M., n=15; ranging from 0.3 to 5.4). The experiment showing 5-fold excess 
of CFP over YFP was an outlier, though, as the next lower expression ratio was 1.3 (i.e. 
only minor overexpression of Gαi1-CFP over YFP-AC5). However, the dataset in 
question yielded no outlying EC50. 
In conclusion, the higher sensitivity observed in the Gαi/AC5-FRET assay in 
comparison to the Gαi/Gβγ-FRET cannot be attributed to differences in receptor 
expression or unfavourable expression levels of the FRET-partners. 
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3.5.2 Verification of the sensitivity of Gαi1/AC5-interaction and Gi1-protein 
activity with endogenous G-proteins using downstream functional readouts 
The experiments described so far to investigate the sensitivity of the Gαi1/AC5-
interaction and the Gi1-protein had relied on heterologous expressed fluorescently 
labelled proteins. This protein overexpression might cause artificial interaction between 
the investigated partners. Endogenous G-proteins were used to verify the observed 
differences between the agonist-dependent sensitivity of G-protein activation and 
Gαi1/AC5-interaction. Because the interaction of unlabelled proteins cannot be easily 
determined, functional downstream readouts were used. The GIRK channel, an effector 
of Gβγ-subunits, is classically used to monitor Gi-protein activity. G-protein-mediated 
regulation of AC5 results in alterations of cAMP levels. Therefore the Gi-protein-
dependent activity of the GIRK channel was compared to the inhibition of cAMP 
production. 
3.5.2.1 GIRK channel activity as a functional readout for Gi1-protein activity 
The initial publication of the Gαi/Gβγ-FRET assay showed that the concentration-
response of the FRET assay very closely resembled that of the GIRK channel activity 
(Bünemann et al., Proc. Natl. Acad. Sci. U. S. A. 2003). In order to verify the 
concentration-response of the Gαi/Gβγ-assay under the given experimental conditions 
collaboration with Dr. Andreas Rinne was established, who performed 
electrophysiological recordings of the GIRK channel (Figure 27). 
 
Figure 27: Receptor-induced GIRK channel activity 
Representative whole-cell patch recording of agonist-induced GIRK currents. The experiments 
were performed at a holding potential of -90 mV and GIRK activity was measured as inward 
currents. The calculated reversing potential EK was -48 mV. The cell was stimulated with the 
indicated concentration of NE. Between two stimulations the agonist was washed off by 
superfusing the cell with agonist-free buffer to allow the baseline recovery of the current (not 
shown). The spikes in the trace are voltage ramps from -120 mV to +60 mV (duration: 500 ms) 
used to generate the voltage-current plot for the channel (right panel). Refer to methods section 
and Rinne et al. (Proc. Natl. Acad. Sci. U. S. A. 2013) for further details on these experiments. 
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For these measurements different concentrations of NE were applied, always including 
500 nM NE for normalisation purposes. The resulting EC50 for the GIRK activity 
concentration-response (Figure 30 later in this section) was very similar to that obtained 
from the Gαi/Gβγ-FRET experiments. 
3.5.2.2 AC regulation assessed by dual control of cAMP generation through Gs- and 
Gi-pathways 
Having confirmed the sensitivity of the Gαi/Gβγ-FRET with a functional readout, the 
Gi-protein-dependent inhibition of cAMP production was to be analysed. However, 
reduction of cellular cAMP levels by activation of inhibitory pathways cannot be easily 
determined. Therefore, a protocol was established to investigate the dual control of 
cAMP generation by stimulatory and inhibitory G-proteins at the same time. HEK293T 
cells were transiently transfected with Epac1-camps, the FRET-based sensor for cAMP, 
together with AC5 and α2A-AR. The cells were continuously superfused with 3 nM Iso 
for 9 min, thereby stimulating cAMP production via endogenous β2-ARs and 
Gs-proteins (Figure 28). During the Iso-application 0.3 nM NE was added to stimulate 
endogenous Gi/o-proteins. The concentration for NE was chosen according to the EC50 
of the Gαi/AC5-FRET-change as detailed above. Application of NE, during the 
continuous treatment with Iso, resulted in a robust increase of the ratio, reflecting cAMP 
degradation. Control experiments without coexpression of either receptor or AC5 
revealed the dependence of this effect on both partners. 
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Figure 28: Dual regulation of cAMP measured with FRET 
HEK cells were transfected with Epac1-camps together with AC5-wt and α2A-AR as indicated to 
measure cAMP levels. The graph shows average traces obtained from 8-10 single-cell 
recordings (mean ± S.E.M.). Stimulation of endogenous β2-ARs by Iso resulted in a loss of 
FRET indicating the generation of cAMP. NE-mediated activation of the cotransfected α2A-AR 
inhibited AC-dependent cAMP generation and increased the FRET again. This occured only in 
cells that were cotransfected with α2A-AR. Cells without cotransfected AC5-wt reacted less to 
both Iso and NE. These recordings were performed with a sampling rate of 0.5 Hz. 
One aspect of the cAMP recordings was especially notable. 0.3 nM NE led to an 
increase in the FRET-ratio that plateaued above the initial baseline before the 
application of Iso. This reflects a decrease of basal cAMP levels of the cells and hinted 
at a very sensitive Gi-dependent regulation of AC5.  
3.5.2.2.1 Dual control of sREACh-labelled AC5 in comparison to wild-type AC5 
As mentioned previously, the CNG-channel-based bioluminescent cAMP-assays failed 
to characterise Gi-mediated AC5-inhibition (compare with section 3.3). In order to 
avoid problems with the combined use of Epac1-camps and YFP-AC5 the 
non-fluorescent construct sREACh-AC5 was cloned. This construct was measured 
under analogous experimental conditions like that depicted in Figure 28 to investigate 
the Gi-signalling competence of the labelled AC5 (Figure 29). 
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Figure 29: Comparison of sREACh-AC5 and AC5-wt with respect to regulation of cAMP 
HEK cells were transfected with Epac1-camps and the indicated constructs to monitor cellular 
[cAMP]. These experiments were performed analogous to those depicted in Figure 28. 
Presented are average curves (mean ± S.E.M.) of 10 recordings for each condition. Note, that 
the traces of non-fluorescently labelled sREACh-AC5 (dark grey) and AC5-wt (black) are very 
similar in kinetics and amplitude. 
sREACh-AC5 reached 95.6 ± 6.1 % (mean ± S.E.M., n=10) of the α2A-AR-induced 
inhibition of cAMP generation of wild-type AC5. The curves were virtually identical, 
confirming that sREACh-AC5 showed also wt-like kinetics of dual control through Gs- 
and Gi-proteins. Together with data from the bioluminescence-assays described in 
section 3.3 YFP-AC5 was considered to be fully Gs- and Gi-signalling-competent as 
well. 
3.5.2.3 Comparison of the concentration-response of cAMP regulation and 
GIRK channel activity 
Similar to the experiments detailed above (section 3.5.2.2) concentration-response 
curves were recorded. Cells were superfused with three increasing concentrations of NE 
during each experiment, always including 3 nM NE for normalisation. These 
experiments revealed that 0.3 nM NE did not elicit the maximum inhibition of cAMP 
generation, but rather about 85 %. The final concentration-response curve had an EC50 
of about 0.08 nM NE, which was even further right-shifted to the already very sensitive 
FRET between Gαi1 and AC5. The curve was also quite steep, with a Hill slope of 5.9, 
which was possibly caused by further amplification mechanisms involved in the 
regulation of cAMP and the non-linear detection of [cAMP] by Epac1-camps. 
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Figure 30: Concentration-response of cAMP regulation and GIRK activity towards 
receptor stimulation 
Concentration-response curves for GIRK channel activity (squares) and NE-mediated inhibition 
of Iso-induced cAMP generation (triangles) were obtained from similar experiments as depicted 
in Figures 27 and 28, respectively. The GIRK channel activity at a given concentration was 
normalised to the maximum activity at 500 nM NE (mean ± S.E.M., n≥5). For this set of cAMP 
experiments three increasing concentrations of NE, always including 3 nM NE, were 
sequentially applied under continuous application of 3 nM Iso. The respective FRET-changes 
were normalised to the maximum FRET-change observed between the application of 3 nM NE 
and the final plateau of 3 nM Iso after NE withdrawal (mean ± S.E.M., n≥7). The data were 
fitted to concentration-response curves resulting in an EC50 of 0.08 nM NE (slope of 5.9) for the 
inhibition of Iso-induced cAMP elevation and 19 nM NE (slope of 0.9) for the GIRK channel 
activity, respectively. 
The comparison of the two functional readouts revealed an even larger left-shift 
between the Gi-protein activity-mediated effect (GIRK) and the Gαi1/AC5-interaction-
mediated regulation of cAMP (EC50 of 19 and 0.08 nM NE, respectively). Both curves 
showed outlying values (0.3 nM NE for cAMP and 30 nM NE for GIRK). These values 
had not been measured together with their respective next lower values. Therefore it 
cannot be concluded, which of the values is more reliable (the lower or higher of each 
pair, respectively). 
3.6 Kinetics of the interaction between YFP-AC5 and Gαi1-CFP upon 
washout of the agonist 
Having ruled out other causes that might shift the sensitivity of the assays (refer to 
sections 3.5.1.1 and 3.5.1.2) the kinetics of the interaction seemed to be a relevant 
mediator of the high sensitivity observed for the Gαi/AC5-FRET in comparison to 
Gi1-protein activation. Considering the G-protein cycle the following hypothesis was 
postulated.  
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Due to the G-protein cycle (compare Figure 3) there is always a fine-tuned balance 
between active and inactive G-protein subunits. An inhibition of G-protein deactivation 
through AC5 would therefore result in a shift towards a larger amount of AC-bound 
active G-protein subunits. This increased amount of active G-proteins should result in a 
higher sensitivity of the assay, which in turn should be visible in a left-shift of 
concentration-response curves. As already reported, this increased sensitivity was 
observed (compare Figure 24). Therefore, the kinetics of G-protein activation and 
Gαi/AC5-FRET were compared under similar experimental conditions. 
 
Figure 31: Interaction between Gαi1-CFP and YFP-AC5 is prolonged in comparison to 
Gi1-protein deactivation 
HEK cells were transfected with either Gαi/Gβγ- or Gαi/AC5-FRET assays and single-cell 
FRET-recordings were performed to analyse agonist-dependent changes in FRET. The 
representative traces (not corrected for bleaching) were aligned to the start of the agonist 
application. Furthermore, the X-axis were interrupted in the plateau of NE application to better 
show the different kinetics of Gi1-protein reassociation and Gαi1/AC5-dissociation. 
Although the amplitudes of the individual assays differed by about a factor of 2, the 
respective onset-kinetics were very similar. This was especially obvious, when both 
assays were scaled to the same amplitude (compare black squares and grey triangles in 
Figure 32). 
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Figure 32: Similar kinetics of Gi1-protein activation and Gαi1/AC5-association 
The average FRET-change upon stimulation with NE is depicted as mean ± S.E.M. for 12 cells 
of each condition. The amplitude of the Gαi/Gβγ-FRET (black squares) is about twice as large 
as that of the Gαi/AC5-FRET assay (black triangles). The grey triangles represent the Gαi/AC5-
data scaled to the amplitude of the Gαi/Gβγ-assay for better comparison of the kinetics. 
In contrast to the similar onset-kinetics of both conditions, the offset after agonist-
withdrawal was significantly delayed. The recovery of the FRET-signal between Gαi1 
and AC5 was prolonged in comparison to the deactivation of the Gi1-protein (Figure 
33, black triangles vs. black squares, respectively). This prolonged interaction between 
AC5 and Gαi1 might slow down the G-protein cycle, as at least the reassociation of the 
Gi1-protein subunits will be delayed. RGS4 was overexpressed to accelerate G-protein 
deactivation and thereby the recovery of the FRET-signal of the Gαi/AC5-condition. As 
shown in Figure 33A, RGS4 significantly accelerated Gi1-protein deactivation. RGS4 
reduced the t0.5 for Gi1-protein deactivation by about 50 % from 29.3 s to 15.8 s. 
However, RGS4 did not significantly influence the dissociation of Gαi1-CFP and 
YFP-AC5 (Figure 33B and C). 
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Figure 33: Kinetics of Gi1-protein deactivation and interaction of Gαi1 and AC5 
A) The representative sample traces depict the agonist-dependent change in FRET between Gαi1 
and Gβ1γ2. RGS4 accelerated the subunit rearrangement upon agonist-washout. The traces were 
normalised to the amplitude of the agonist-induced FRET-change. B) The average traces 
(mean ± S.E.M., n≥12) show the normalised agonist washout phase after withdrawal of 10 nM 
NE. RGS4 accelerated Gi1-protein deactivation and subunit reassociation in comparison to the 
RGS4-free condition. The generally slower dissociation kinetics of the Gαi/AC5-FRET assay 
was not affected by RGS4. C) The bar graph presents the average t0.5 of the conditions presented 
in B (mean ± S.E.M., n≥12). Gi1-protein deactivation took about half as long as Gαi1/AC5-
dissociation. The difference was even larger, if RGS4 was cotransfected. Statistics were 
obtained using ANOVA and Bonferroni’s post-hoc test (*: p<0.05; ns: not significant). 
Because of the prolonged interaction between Gαi1 and AC5 it was concluded that AC5 
shifted the balance of the G-protein cycle, thereby causing the higher sensitivity 
observed in comparison to Gi1-protein activity. However, these experiments did not 
allow to determine, whether AC5 shows prolonged interaction with Gαi1-GTP or 
Gαi1-GDP. 
3.6.1 Long components in the Gαi1/AC5-interaction detected by FRET 
Experiments, as depicted in Figure 21, revealed a tendency for incomplete recovery of 
the FRET-signal between Gαi1-CFP and YFP-AC5. This hinted at the presence of 
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additional long components in the FRET-signal. To investigate this in more detail cells 
were stimulated twice with 1 µM NE with different washout times in between. A long 
component would delay the recovery of the Gαi/AC5-FRET-signal back to baseline. 
Conclusively, a second stimulation would not be elicited from the initial baseline, but 
from an elevated value according to the washout of the preceding stimulation. This 
would reduce the actual agonist-induced amplitude of the second stimulation. However, 
the longer the washout between the two stimulations, the further the ratio should have 
recovered to baseline and the second amplitude should ultimately be similar to the first 
one. Figure 34A (next page) presents a representative stimulation of such an 
experimental setting. 5 min of washing between the stimulations only recover the 
second amplitude by about 56.5 ± 10.1 % (mean ± S.E.M., n=14). 
Between two stimulations the agonist was washed out for 2, 5 or 10 minutes. The 
amplitude of both stimulations was compared, as well as the transient increase over the 
agonist-dependent FRET-change. Even 10 minutes of agonist washout between the 
stimulations only recovered the second amplitude by about 76 ± 7.7 % (n=11). 
Contrastingly, 2 minutes of agonist washout recover the amplitude of the Gαi/Gβγ-
FRET by 90.6 ± 4.5 % (n=3). The transient of the Gαi/AC5-FRET-signal was not 
affected by the different washout times. These results provide evidence for the presence 
of further, very slow components in the interaction between Gαi1 and AC5 that might 
contribute to the high sensitivity. Future studies are necessary to reveal possible 
underlying mechanisms. 
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Figure 34: Amplitude of a second stimulation of Gαi/AC5-FRET after different times of 
agonist washout 
Cells transfected with the Gαi/AC5-FRET assay were stimulated for 30 s with NE. The agonist 
was washed out for 2, 5 or 10 minutes, before being applied a second time. Panel A shows a 
representative recording of such an experiment with 5 minutes of washout between the 
stimulations. The recording was corrected for bleaching using the maximum of the transients 
and the agonist-evoked amplitude as references. Furthermore, the curve was smoothened using 
Savitzky-Golay algorism. S0 is the amplitude of the reference, first stimulation, calculated as the 
difference in FRET before and during agonist application. The amplitude of the second 
stimulation after 5 minutes of agonist washout (S5) was measured as the difference between the 
agonist-evoked amplitude and the FRET-ratio prior to this stimulation (grey line). The 
amplitude of the transients (T0 and T5) was measured as the difference in FRET between the 
agonist-induced amplitude and the transients’ maxima. Amplitude and transient change of the 
second agonist application (S5 and T5, in this example) were normalised to those evoked by the 
reference application. B) The bar graph compares agonist-stimulated amplitude and the transient 
increase of the second stimulation with the according reference values. The actual agonist-
induced amplitude increased with longer washout times. Statistics were obtained using ANOVA 
and Dunnett’s multiple comparison test (*, p≤0.01; ***, p≤0.001). All transient values after 
washout are not significantly different from the first transient, which is not indicated in the 
figure.  
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4 Discussion 
Regulation of the second messenger cAMP is the common outcome of stimulatory and 
inhibitory G-protein signalling. The development of optical methods, as reviewed by 
Lohse et al. (Pharmacol. Rev. 2012), together with structural information (Sunahara et 
al., Annu. Rev. Pharmacol. Toxicol. 1996; Tesmer and Sprang, Curr. Opin. Struct. Biol. 
1998) and data from reconstituted systems for purified proteins, reviewed by Albert 
Gilman (Annu. Rev. Pharmacol. Toxicol. 2012), painted a detailed picture of the 
regulatory mechanisms in the signalling pathway from GPCR to cAMP. However, 
research on ACs has been hampered for several reasons. Currently, no full-length 
structure of the mammalian enzyme is available, not least because of the enzyme’s size 
and hydrophobicity (Gilman, Annu. Rev. Pharmacol. Toxicol. 2012). Therefore, 
interaction sites and conformational changes in the transition from inactive to active 
state can only be guessed to a certain extent from the biochemical data available. 
Immunological methods like Western-Blotting and immunofluorescence are impaired 
by the lack of suitable antibodies that specifically detect individual isoforms and 
discriminate for example between AC5 and AC6. Furthermore, fluorescently labelled 
ACs have been reported to not always localise to the plasma membrane (Sadana et al., 
Mol. Pharmacol. 2009), a problem possibly interfering with interaction studies with 
other membrane-bound proteins like receptors or G-proteins. Altogether research on 
ACs is difficult. Some studies already utilised FRET and BRET (Bioluminescence 
Resonance Energy Transfer) to investigate direct interaction between ACs, receptors 
and G-proteins (Sadana et al., Mol. Pharmacol. 2009; Rebois et al., Cell. Signal. 2012), 
but those experiments were performed under steady-state conditions. Investigation of 
AC-dynamics had to rely on cAMP measurements and the dynamics of the interaction 
between ACs and their respective signalling partners remained elusive. 
This study closed a gap in the available microscopic assays of the signalling pathway 
from GPCR to cAMP and thereby provides a new tool to perform biochemical research 
on ACs in intact cells. Fluorescently labelled AC isoforms were cloned and investigated 
together with fluorescent G-protein subunits using FRET-microscopy. Using the newly 
developed assay the agonist-dependent dynamic interaction between AC5 and several 
G-protein subunits (Gαs, Gαi1 and Gβ1γ2) was resolved. Furthermore, a highly sensitive 
Gαi1-mediated inhibition of AC5 compared to other Gi-protein effectors was observed 
 Discussion 
76 
 
and evidence gathered that the interaction dynamics between AC5 and Gαi1 are a major 
contributor to the high sensitivity of cAMP regulation. 
4.1 Interaction of YFP-AC5 with G-protein subunits 
YFP-AC5, the brightest of the newly cloned constructs, was similar to a fluorescently 
labelled AC5 previously published by Carmen W. Dessauer’s group (Sadana et al., Mol. 
Pharmacol. 2009), which had served as a template. However, it is essential to control 
proper functionality of proteins that were tagged with GFP derivatives. 
It was noticed that overexpressed fluorescently labelled AC5 tended to localise to 
intracellular compartments, a fact also reported by others (Sadana et al., Mol. 
Pharmacol. 2009). Experiments designed to determine the subcellular localisation of 
endogenous ACs failed, because of the lack of suitable antibodies (Figure 9). Problems 
concerning the specificity of antibodies against ACs have also been reported previously 
(Gottle et al., J. Pharmacol. Exp. Ther. 2009). Therefore, it can currently not be 
concluded, whether the intracellular distribution reflects the natural expression pattern 
or is an artefact of the overexpression and/or fluorescent label. 
The functionality of the newly generated construct was investigated by means of cAMP 
generation assays. YFP-labelled AC5 showed wild-type-like (wt-like) regulation 
through Gs- and Gi-proteins alike. Bioluminescence-based cAMP-assays (Wunder et 
al., Mol. Pharmacol. 2008) revealed a two-component concentration-response to 
forskolin stimulation in cells that expressed either YFP-AC5 or AC5-wt (Figure 10). 
However, forskolin can permeate cell membranes and activate intracellular ACs, 
including overexpressed ACs that were not trafficked to the membrane and might 
therefore not be under the control of G-proteins. A second set of experiments, where 
cAMP generation was enhanced by stimulating the Gs-pathway, showed that YFP-AC5 
was basically indistinguishable from AC5-wt (Figure 11). Detection of Gi-mediated 
inhibition of cAMP levels is hard to determine with most assays, because those assays 
usually use cAMP increase-based readouts. Therefore, Gi-dependent regulation of 
YFP-AC5 could not be investigated using the bioluminescent assays. The FRET-based 
cAMP sensor Epac1-camps (Nikolaev et al., J. Biol. Chem. 2004) can detect dynamic 
changes in cellular cAMP levels and thereby resolve Gi-dependent inhibition of 
Gs-induced cAMP generation. However, YFP-AC5 regulation could not be investigated 
directly by Epac1-camps experiments, because the fluorophore of the AC would have 
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severely impaired the sensor’s signal/noise-ratio. sREACh (Murakoshi et al., Brain Cell 
Biol. 2008) is a variant of YFP that was cloned to be non-fluorescent, but has otherwise 
equal protein properties (i.e. size and build) like the other GFP derivatives. It was 
therefore cloned to AC5 to generate a non-fluorescent construct that closely resembled 
YFP-AC5. sREACh-AC5 was used to assess dual control by Gs- and Gi-proteins using 
Epac1-camps and showed the same course of cAMP-generation and -inhibition as 
wild-type AC5 (Figure 29). Taken together YFP-AC5 was concluded to be fully 
functional and under proper dual control through stimulatory and inhibitory G-proteins. 
The kinetics of the interaction between proteins could be affected by the fusion of 
fluorescent labels, although the labelled proteins retain their functionality. This was, for 
example, reported for the interaction between Gαi3 and GIRK channels, where tagging 
with fluorescent proteins slowed the interaction under certain conditions (Berlin et al., J. 
Biol. Chem. 2011). However, in the present study fluorescently labelled AC5 showed 
wt-like kinetics of Gs- and Gi-mediated regulation of cAMP (Figure 29), arguing 
against this hypothesis. Further functional or regulatory impairments cannot be ruled 
out. To properly investigate this, unlabelled, preferentially endogenously expressed 
proteins should be used. However, there are currently no suitable methods available to 
investigate such interactions in living cells. 
Biochemical studies proposed complexes of AC2 and AC5 with G-protein subunits 
(Rebois et al., J. Cell Sci. 2006; Sadana et al., Mol. Pharmacol. 2009). By means of 
donor fluorescence recovery after acceptor photobleaching no specific interaction 
between G-protein subunits and AC5 was detected in the absence of agonist-stimulation 
(Figure 12). These results argue against the existence of preformed complexes. 
However, they do not rule them out entirely, either. Under non-stimulated conditions 
the orientation of the fluorophores might be unfavourable and/or the distance between 
them might be too large for FRET to occur. The fast onset-kinetics between G-protein 
subunits and AC5 (Figures 17 and 32), which are in the same range as the G-protein 
activation-kinetics (Bünemann et al., Proc. Natl. Acad. Sci. U. S. A. 2003; Hein et al., J. 
Biol. Chem. 2006), argue in favour of signalling complexes. In the course of this study 
the presence of preformed complexes was not investigated further. Nevertheless, future 
studies could address this, e.g. by using dual colour fluorescence recovery after 
photobleaching assays (FRAP) as described by Dorsch et al. (Nat. Methods 2009).  
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The interaction between a GPCR (α2A-AR) and AC5 was investigated, but no FRET 
was observed (Figure 13). A signalling complex between AC2, Gs-proteins and 
β2-adrenergic receptors has been reported in a study using BRET (Rebois et al., Cell. 
Signal. 2012) and co-immunoprecipitation revealed interaction between the β2-AR and 
AC5/6 (Lavine et al., J. Biol. Chem. 2002). The BRET-experiments had a larger Förster 
radius than the FRET-pair used in this study and might therefore resolve interactions 
over distances that might be too large for FRET. As the basal interaction between the 
receptor and the AC by means of donor fluorescence recovery after acceptor 
photobleaching was not determined in this study, it remains an open question, whether 
the observations for the β2-AR and type II and V ACs would also hold true for the 
α2A-AR and AC5. 
Upon agonist application a FRET-signal developed between all investigated CFP-
labelled G-protein subunits and YFP-AC5. The FRET-amplitudes observed in the 
experiments (Figure 14 and 32) were small in comparison to other FRET assays 
(Bünemann et al., Proc. Natl. Acad. Sci. U. S. A. 2003; Hein et al., J. Biol. Chem. 2006; 
Wolters and Bünemann, Naunyn-Schmiedeberg's Arch. Pharmacol. 2013). This 
limitation might be caused by a distance between the fluorophores larger than the 
Förster radius or an unfavourable orientation. In context of the interaction between 
G-proteins the amplitude of the FRET-change is of less importance, though. 
Furthermore, the observed low signal/noise-ratio was probably due to the low 
expression of the labelled partners. However small, the signals were reproducible and 
their specificity was proven by the opposing course of the individual fluorescence 
traces, the reversibility of the signal upon agonist withdrawal and the kinetics of the 
FRET-changes. Furthermore, no such FRET-changes were observed upon replacement 
of YFP-AC5 with control proteins such as CD86-YFP (Dorsch et al., Nat. Methods 
2009), a T-cell receptor that does not interact with G-proteins (Figures 19). In addition, 
FRET-changes remained consistent upon exchange of the receptor and also when the 
fluorophores were exchanged (Figures 15 and 18).  
The specificity of the observed FRET-signals between AC5 and the different G-protein 
subunits was further controlled by negative control experiments with non-AC5-
interacting G-proteins. Gq-proteins are not presumed to interact with ACs at all, their 
effectors being phospholipases. Go-proteins have also been reported to not interact with 
AC5 (Xie et al., Sci. Signal. 2012). These proteins might be even better suited as a 
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negative control, because they belong to the same family as the AC5-interacting 
Gi-proteins. FRET occurred in neither combination (Figures 16 and 22), which verified 
the observations for the other G-protein subunits. 
Although the amplitudes of the newly developed assays were small, they were still 
reliable. The signal/noise-ratio was sufficient to reveal distinct signal-“phenotypes” for 
the interaction between AC5 and different G-protein subunits. It further resolved 
divergences in sensitivity and interaction-kinetics in the Gi-protein/AC-pathway, which 
will be discussed later in this section. 
Agonist-mediated interaction between Gαs or Gs-derived Gβ1γ2 and AC5 resulted in the 
development of FRET with similar onset-kinetics and only slightly different plateau 
values (Figures 14-17). The t0.5 to maximum stimulation of these interactions is in the 
same range as observed previously for the activation of Gs-proteins (Hein et al., J. Biol. 
Chem. 2006), although a different receptor (β2-AR instead of β1-AR) was used. Previous 
reports of FRET-assays revealed a kinetic gap between the activation of the G-protein 
and the generation of cAMP, the t0.5 being in the sub-second range and 30 s, 
respectively) (Nikolaev et al., J. Biol. Chem. 2004; Hein et al., J. Biol. Chem. 2006). 
During these studies it became evident that the interaction between the G-protein and 
AC5 is not the rate-limiting step in the signalling-cascade from GPCR to cAMP. Given 
the fast onset kinetics of Epac1-camps observed in vitro of less than 2 s (Nikolaev et al., 
J. Biol. Chem. 2004) and the fast diffusion of cAMP in cells, the enzymatic rate of AC5 
presumably in combination with cAMP-degredation through PDEs is most likely the 
cause for the observed delay. 
The observation of FRET between AC5 and Gαs and Gs-derived Gβγ is in line with 
previous reports about the joint regulation of AC5 by all Gs-protein subunits (Sadana et 
al., Mol. Pharmacol. 2009). Interestingly, however, the FRET-signals between AC5 and 
the different subunits were easily distinguishable. While the interaction between 
Gs-derived Gβγ and AC5 showed exponential onset-kinetics as observed in G-protein-
FRET assays, Gαs produced a transient peak before the final plateau. This peak was not 
affected by exchange of the receptor or “swapping” of the fluorescent proteins (Figures 
15). At lower concentrations it seemed to be missing, but onset-kinetics were so slow, 
that the development of the peak might have been blunted. As the transient peak was 
not observed with Gβγ-subunits, it is unlikely to be due to events upstream of the 
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Gs-protein/AC5-interaction, such as Gs-protein activity. Due to the lack of full-length 
structures of AC5, it can currently only be speculated about the precise nature of this 
observation. The group of Carmen W. Dessauer reported that the AC’s N-terminus is 
involved in the interaction with Gβγ-subunits, provides a binding site for Gαs-GDP and 
also interacts with the catalytic core (C1-domain) (Mol. Pharmacol. 2009). The authors 
speculate that this interaction enhances or facilitates binding of Gαs-GTP to the AC’s 
catalytic domain C2. Gαs has been shown to interact with C1 and C2 domains (Sunahara 
et al., J. Biol. Chem. 1997; Tesmer et al., Science 1997), presumably to bring the two 
domains into the closed/active conformation. Taken together it can be imagined, that the 
observed transient peak in FRET reflects a combination of conformational changes that 
occur in the Gαs/AC5-complex. This could e.g. be the transition of the activated 
Gαs-subunit from the binding site on the N-terminus (where the AC is labelled) to that 
on the catalytic core. A C-terminally labelled AC might result in a different FRET-
signal between these two partners and provide further insight. However, this speculative 
hypothesis needs experimental verification. 
FRET was not only observed between AC5 and Gs-derived Gβ1γ2-subunits, but also 
with Gβ1γ2 from Gi-proteins. The resulting signals were virtually identical with regard 
to amplitudes and kinetics. So far there have been no reports about different interaction 
sites for the two Gβγ-populations. The current results hint at binding to the same site. 
Furthermore, no reports on competition between Gs- and Gi-derived Gβγ for the same 
binding site were found. This question was not addressed in this study, though. It might 
be possible to investigate this by FRET between labelled Gβγ-subunits and AC5 in the 
presence of Gαs and Gαi1. If there are two competing pools of Gβγ, the activation of one 
pathway (e.g. Gs) should reduce the signal evoked by the other (e.g. Gi). It has been 
reported that Gs- and Gi-proteins may compete for the pool of Gβγ (Hippe et al., 
Naunyn-Schmiedeberg's Arch. Pharmacol. 2013). In the heterologous overexpression 
system usually used for FRET-studies like the current one, the expression of Gβγ will 
most likely not be limiting, though. However, the stoichiometry between Gβγ and AC5 
should be controlled in such experiments. Gβγ is usually better expressed at the cell 
membrane than AC5. Therefore, it might be preferable to use Cerulean or CFP-tagged 
AC5. This would not only prevent early saturation of the FRET-signal that could occur 
if the donor-labelled Gβγ is expressed in excess of the acceptor-carrying AC5, but also a 
reduction of the signal/noise-ratio. 
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After the observations described above, agonist-dependent FRET-changes between Gαi1 
and AC5 were investigated. Interestingly, this interaction showed a new signal 
phenotype. While the onset-kinetics fairly much resembled that of the Gαi/Gβγ-assay 
(Figure 32), compare also (Bünemann et al., Proc. Natl. Acad. Sci. U. S. A. 2003), and 
being only insignificantly slower than the interaction between AC5 and Gs-proteins 
(Figure 15 and 17), the offset was completely different. In contrast to the exponential 
recovery observed in the Gαi/Gβγ-assay, this interaction showed an additional transient 
increase in the FRET-ratio upon agonist-washout, before recovering to baseline (Figures 
31 and 33). Even more interestingly, very long kinetic components seemed to be 
involved in this interaction (Figures 34), which reduced the amplitude of a second 
stimulation (see also section 4.3 for a detailed discussion). 
Several explanations can be imagined for the observed transient increase in the FRET-
ratio between Gαi1 and AC5. It might be due to self-inhibitory properties of the α2A-AR 
as have been previously reported (Hommers et al., J. Biol. Chem. 2010). In line with 
this hypothesis is the observation that the actual FRET-amplitude was reduced at higher 
agonist-concentrations, while the overall-amplitude (maximum amplitude of the 
transient) was not affected (see Figure 21 for an example). The self-inhibition of the 
signalling pathway should result in a bell-shaped concentration-response for cAMP 
regulation. Such an effect was not observed, though, at least not in the concentration 
range that could be tested in these studies. Because NE is also an agonist on the β2-AR, 
which is endogenously expressed in HEK293T cells, more than 10 nM NE reliably 
stimulated this receptor and resulted in cAMP generation. This cross-signalling did not 
allow to measure cAMP concentration-responses at more 10 nM NE. 10 nM NE was 
about the lowest concentration that reliably elicited the transient increase upon agonist 
washout, and the expected bell-shape might only occur above this concentration. 
Contrastingly, the FRET between Gi-derived Gβγ and AC5 was virtually identical to 
that observed between AC5 and Gs-derived Gβγ and showed no signs of self-inhibitory 
components. This argues against such a mechanism. On the other hand, the observed 
transient might reflect yet another conformational change, that occurs after the agonist 
is withdrawn and the signalling complex between Gαi1 and AC5 resumes its initial 
conformation again. This hypothesis is strengthened by the observation, that agonist-
application within the transient leads to a decline in the FRET-ratio back to the initial 
amplitude of the previous stimulation (Figure 21). The existence of larger signalling 
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complexes (Rebois et al., Cell. Signal. 2012), that include Gs- and Gi-proteins, their 
respective receptors and AC5, might explain both observations. However, based on the 
results from acceptor photobleaching experiments, no indication for such complexes 
was observed in this study.  
4.2 Sensitivity of G-protein-mediated regulation of AC5 
Preliminary experiments had hinted at a very sensitive interaction between Gαi1 and 
AC5, a result verified in the later course of this work. The actual interaction between the 
partners was found to be 10-times more sensitive towards agonist-mediated stimulation, 
than expected from the activity of the Gi1-protein (Figure 24). Li et al. had reported the 
different sensitivity of cAMP- and G-protein-dependent pathways in frog cardiac 
myocytes (J. Gen. Physiol. 1994). They observed two distinct effects of M2-AChR 
stimulation, which in their sensitivity were also shifted by more than one order of 
magnitude: The cAMP-dependent inhibition of Ca
2+
 currents occurred at lower agonist 
concentrations than necessary to activate GIRK channels in a Gi-protein activity-
dependent manner. Furthermore, the dopamine D3 receptor, a receptor that only weakly 
activates Gi-proteins, had been reported to efficiently inhibit AC5 (Robinson and Caron, 
Mol. Pharmacol. 1997). These studies hinted at a very sensitive inhibition of ACs, 
especially AC5, through Gi-proteins. Both studies used cAMP production or even 
further downstream effects as readouts and they might have been influenced by 
downstream regulatory mechanisms or the stoichiometry of the expressed partners. 
Therefore, the underlying mechanism for the increased sensitivity remained elusive. The 
results reported herein indicate that the direct interaction between Gαi1 and AC5 already 
causes this sensitivity-shift. 
Physiologically the possibility to increase the sensitivity of the regulation of one 
effector over the other could be highly relevant. It would allow for huge differences in 
the regulation of several effectors by the same pool of receptors and G-protein subtypes 
in identical cells and thereby provide a potent fine-tuning mechanism for cellular 
responses. Evidence for such divergence was found, when the regulation of targets 
downstream of G-protein activity and G-protein/AC5-interaction was investigated. The 
higher sensitivity observed in the Gαi1/AC5-interaction also translated into functional 
readout. The Gi-mediated inhibition of AC5-dependent cAMP production was even 
more significantly left-shifted in comparison to GIRK activity, than the Gαi1/AC5-
interaction was compared to the Gi1-protein activation. The obtained EC50-values 
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differed by more than two orders of magnitude. It must be noted, that the concentration-
response of the GIRK channel, as measured in collaboration by Dr. Andreas Rinne 
under similar experimental conditions, was slightly right-shifted in comparison to the 
Gi1-protein activity (EC50 of 19 nM and 3 nM NE, respectively). Bünemann et al. 
showed, that GIRK channel activity closely resembles Gi1-protein activity, as assessed 
by FRET (Proc. Natl. Acad. Sci. U. S. A. 2003). The concentration-response curves 
presented in Figure 30 seem to include outlying values. These values lie in the steepest 
part of the curve and thereby negatively affect curve fitting and EC50 calculation. Due to 
the experimental settings, these values could not be measured with their entire 
respective neighbours at the same time. Nevertheless, the curves are shifted further apart 
than the Gαi1/AC5-interaction and Gi1-protein activation, which is possibly caused by 
further regulatory mechanisms in the functional assays. The steepness of the cAMP-
inhibition concentration-response-curve (slope of 5.9) hints at such effects. At this point 
it should be noted, that the cAMP measurements, as detailed above, were conducted 
without cotransfected G-proteins. The dual control of AC5 relies on Gs- and 
Gi/o-proteins endogenously expressed in HEK cells. Go-proteins obviously do not 
interact with AC5 (Xie et al., Sci. Signal. 2012) and are therefore unlikely to attribute to 
the observed effect. HEK293T cells do not express large quantities of Gαi1-subunits 
either. Therefore, Gi2/3-proteins are presumable major contributors to the observed 
strong inhibition of AC5-dependent Gs-stimulated cAMP elevation. Although this 
remains speculative, it seems likely that the observations reported herein for the 
interaction between Gαi1 and AC5 would also hold true for Gαi2 and Gαi3. 
It was noted during the investigation of the dual control of AC5-mediated cAMP 
production through Gs- and Gi-proteins, that the Iso-stimulated cAMP generation was 
more than completely inhibited by activation of inhibitory pathways with 0.3 nM NE. 
This became obvious in the fact that the FRET-ratio would increase to levels above the 
initial baseline value, which indicated a reduction of cAMP below the basal level of the 
cell, prior to stimulation (Figures 28 and 29). This might be caused by the not-saturating 
stimulation of ACs through 3 nM Iso. It has been reported that Gi-proteins cannot 
completely inhibit AC5, if this is fully activated by large amounts of Gαs in combination 
with forskolin (Chen-Goodspeed et al., J. Biol. Chem. 2005). However, the Epac1-
camps-based cAMP measurements relied on endogenous G-protein levels, in which 
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Gi-proteins might be more abundant than Gs-proteins, thereby dominating AC5-
regulation. 
The high sensitivity observed in the Gαi1/AC5-interaction could have several reasons. 
First, the receptor expression in the AC5-including assay might be higher than in the 
Gαi/Gβγ-assay. This would shift the apparent sensitivity to the left. As assessed by 
Western-Blot-analysis, the expression of the receptor was about equal in both assays 
(Figure 25). If at all, it was slightly less in the Gαi/AC5-cells (Figure 25). Altogether 
different receptor expression levels were ruled out to cause the observed shift. Another 
possible explanation might be found in a different stoichiometry of the FRET-partners. 
Should the FRET donor, i.e. Gαi1-CFP, be expressed in excess of the acceptor, i.e. 
YFP-AC5, the resulting interaction would be saturated at low amounts of activated 
G-proteins. One usually aims for a higher expression of the FRET-acceptor than -donor. 
In the assay presented herein, this was not easily achievable, because of the already 
discussed low membrane expression of YFP-AC5. Making use of a control plasmid 
containing CFP and YFP (Dorsch et al., Nat. Methods 2009), the stoichiometry of the 
partners at the cell membrane was analysed (Figure 26). On average, both partners are 
expressed about equally in the Gαi1/AC5-interaction assays. In conclusion, differences 
in membrane expression levels were also ruled out to cause the shifted sensitivity. 
Therefore, the kinetics of the interaction remained the most likely explanation. 
4.3 Prolonged kinetics of the Gαi1/AC5-interaction  
As detailed in the introduction (see section 1.2.4) G-proteins cycle through their 
activation and deactivation process. The already discussed high sensitivity led to the 
hypothesis that AC5 possibly interferes with the dynamics of the G-protein cycle 
(Figure 35). As the G-protein cycle provides a fine-tuned balance between active and 
inactive G-proteins, the prolongation of the active state of the G-proteins could possibly 
shift this equilibrium. If AC5 would now prevent the deactivation of the Gi-protein, 
then the amount of active G-proteins bound to AC5 would be increased, resulting in a 
left-shifted sensitivity of the assay. 
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Figure 35: Possible interaction of AC5 with the G-protein cycle 
AC5 slows the Gi-protein cycle and thereby causes a shift in the balance between active and 
inactive Gi-proteins. 
To investigate this further, interaction kinetics between Gαi1 and AC5 were compared to 
that of the Gi1-protein as assessed by Gαi/Gβγ-FRET. Even though the amplitude of 
both assays differs by about a factor of 2, the onset-kinetics were very similar (Figure 
32). Contrastingly, the offset-kinetics were significantly different. The deactivation of 
the Gi1-protein occured with a half-time of about 30 s while the interaction between 
Gαi1 and AC5 lasted longer (t0.5 is about 43 s). 
The regulator of G-protein signalling type 4 (RGS4) is known to enhance the GTPase 
activity of Gαi1 in vitro and thereby accelerate G-protein-deactivation in vivo (Doupnik 
et al., Proc. Natl. Acad. Sci. U. S. A. 1997). Accordingly, RGS4 significantly 
accelerated G-protein deactivation. Contrastingly, RGS4 failed to reduce the interaction 
of Gαi1 with AC5 and the dissociation time was not significantly affected (Figure 33). 
At this point, it is hard to say, whether the prolonged interaction between Gαi1 and AC5 
is the result of either a slower GTPase activity of the Gαi1-subunit or the prolonged 
interaction between AC5 and Gαi1-GDP. During these studies, RGS4 was not 
coexpressed with the functional cAMP experiments discussed in section 4.2. However, 
RGS4 showed no significant effect on the concentration-response of the Gαi1/AC5-
interaction or Gi-protein activation (Figure 24) and the interaction-kinetics (Figure 33). 
It is therefore likely that cAMP-measurements will not be affected, either. Biochemical 
studies revealed on the other hand that AC5 is regulated by Gαi1-GTP and Gαi1-GDP to 
similar extent (Dessauer et al., J. Biol. Chem. 1998). Presumably, the dissociation of 
Gαi1 from AC5 and the reassociation of the former with Gβγ to the inactive heterotrimer 
is the main cause to relieve the inhibitory effect on AC5. Therefore, on a functional 
level, the question of whether AC5 shows prolonged interaction with Gαi1-GTP 
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or -GDP might be less relevant. The lack of effect of RGS4 on interaction kinetics 
between Gαi1 and AC5 could have different reasons. RGS4 binding to the Gαi1-subunit 
could be sterically hindered and accordingly the Gαi1-subunit is retained in its active 
state for a longer period. It can also be imagined, that RGS4 deactivates the 
Gαi1-subunit in a normal time-course, but Gαi1-GDP stays bound to the AC, which 
delays reassembly of the inactive Gi1-protein. Furthermore, AC5 could reduce the 
endogenous GTPase activity of Gαi1 and thereby prolong the interaction. Which of the 
mentioned reasons is likely, or whether further mechanisms are contributing to the long 
interaction between AC5 and Gαi1 can currently not be answered. However, the 
observed prolonged interaction likely causes a shift in the equilibrium of the G-protein 
cycle and thereby provides an explanation for the observed higher sensitivity. 
It could be argued that RGS4, which accelerates the G-protein deactivation, should 
accordingly right-shift the concentration-response of the G-protein activity or 
Gαi1/AC5-interaction. Even though RGS4-coexpression indeed tended to reduce the 
sensitivity of either assay (Figure 24), the effect did not reach statistical significance. 
This is in line with previous reports (Doupnik et al., Proc. Natl. Acad. Sci. U. S. A. 
1997), but there is no consensus about the underlying mechanism. 
A discrepancy remains between the shift in the sensitivity of the interaction and that in 
kinetics. Whereas the interaction of Gαi1 and AC5 is 10-times more sensitive than the 
activation of Gi1-proteins, their offset-kinetics are only separated by a factor of about 
1.5. Therefore the prolonged interaction between the partners might not be the only 
cause for the increased sensitivity. The low expression of the fluorophores makes the 
assay prone to bleaching, which can “imitate” recovery of the FRET-ratio. In 
combination with the small amplitude, the assay might not be sensitive enough to 
resolve minor differences between real and “bleaching-accelerated” recovery. 
Especially because of the bleaching, the experimental setup might not have been long 
enough to properly resolve the kinetics. However, the hypothesis of a prolonged 
interaction is strengthened by a phenomenon observed at higher concentration of 
agonist. Especially if larger amounts of receptor were expressed, application of agonist 
resulted in a very slow recovery of the Gαi1/AC5-interaction. Even after 10 minutes of 
agonist washout, a second stimulation would only reach about 80 % of the amplitude of 
the initial stimulation (Figure 34). It remains elusive, though, why this long component 
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was less important, if not totally missing at 10 nM NE, the concentration used for the 
actual kinetics experiments (Figure 33). 
To the author’s knowledge, this study provides the first direct evidence, that the 
interaction between an effector and the G-protein can actually prolong the G-protein 
cycle of the effector-associated pool of G-proteins. This in turn results in an increased 
sensitivity of the G-protein-mediated regulation of the effector. Whether AC5 could or 
would alter the kinetics of the Gαi/Gβγ-FRET assay, remains an open question. As 
already discussed, AC5 does not always localise to the plasma membrane, if expressed 
in higher amounts. In order to investigate an influence of AC5 on the Gαi/Gβγ-FRET 
assay, AC5 would have to be expressed in excess to the fluorescent G-protein at the cell 
membrane. Currently there are no experimental conditions that would ensure this and 
accordingly this open question cannot be addressed. 
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4.4 Conclusion 
This work reports the generation of a FRET-based assay to investigate the dynamics of 
the interaction between G-protein-subunits and AC5, thereby complementing the tool-
box of microscopic methods for the GPCR/G-protein/effector signalling pathway. 
Furthermore, a protocol was established to resolve Gi-protein-mediated regulation of 
cellular cAMP. The new FRET-assays resolved the interaction between AC5 and 
different G-protein subunits. A basal interaction between inactive G-proteins and AC5 
was not observed, but agonist-mediated changes in FRET were resolved. Notably, the 
interaction between AC5 and different G-protein subunits also resulted in different 
FRET-signal phenotypes. These reflect most likely different conformational changes 
upon agonist-mediated interaction, possibly involving several steps. The agonist-
dependent interaction between G-proteins and AC5 occurred fast, the onset half-times 
being in the range of 300 ms. This is much closer to the already reported half-times of 
G-protein activation (also being in the sub-second range), than to the half-time of 
cAMP-production (t0.5 of about 30 s). The rate-limiting step in the signalling cascade 
from GPCR to cAMP is therefore presumably the enzymatic activity of AC5 with only 
little influence by the subsequent detection of cAMP by the FRET-based Epac1-camps. 
In addition to the kinetic analysis, an increased sensitivity towards agonist-mediated 
stimulation of the interaction between Gαi1 and AC5 was observed in comparison to the 
activity of the Gi1-protein. This shifted sensitivity became even more evident, when the 
according functional consequences, cAMP production and GIRK channel activity, 
respectively, were investigated. The high sensitivity of the molecular interaction of Gαi1 
and AC5 could explain the differences observed between cAMP-dependent and 
Gi-protein activity-mediated effects reported herein and previously (Li et al., J. Gen. 
Physiol. 1994). Different kinetics of the Gαi1/AC5-dissociation and the Gi1-protein 
deactivation provide a putative mechanism for the extreme sensitivity of AC5 towards 
Gi-dependent regulation. RGS4 did not affect the kinetics of AC5-bound G-proteins, 
which hints at an AC5-dependent slowing of the G-protein cycle, because the 
reassembly of the inactive G-protein is inhibited. Taken together this leads to the 
hypothesis that the dynamics of G-protein/effector-interactions might serve to fine-tune 
GPCR-mediated signal transduction in an effector-dependent manner. 
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5 Summary 
The signalling pathway from G-protein-coupled receptors to the second messenger 
cAMP is present in virtually all cells and of major physiological and pathophysiological 
importance. The membrane-spanning receptors can easily be targeted by pharmaceutical 
compounds and therapies to treat diseases like hypertension, asthma or pain affect 
cellular cAMP-levels. Biochemical studies have revealed a lot of important information 
about the interaction of the proteins participating in this signalling cascade, namely the 
receptors, the G-proteins and adenylyl cyclases. The development of new microscopic 
methods allowed to dynamically investigate protein/protein-interactions. While these 
techniques have already been widely used to investigate in vivo signalling dynamics of 
the receptors, G-proteins and second messengers, research on adenylyl cyclases (ACs) 
mainly relied on in vitro methods or steady-state interaction studies. 
An assay, based on Förster Resonance Energy Transfer (FRET), was developed within 
this study, to investigate the dynamic interaction between G-proteins and ACs in living 
cells, thereby providing a platform for biochemical analysis in vivo. Furthermore, a 
protocol was established to resolve Gi-protein-mediated regulation of cAMP in single 
living cells by means of FRET. For the assays, a fluorescently labelled AC5 was cloned. 
Bioluminescence-based cAMP measurements proved the constructs wild-type-like 
functionality with respect to stimulation through forskolin and Gs-proteins. The new 
protocol for FRET-based cAMP measurements verified Gs- and Gi-protein signalling 
competence of the labelled AC5. 
The new assay was used to analyse agonist-dependent interaction between AC5 and 
Gαs-, Gαi1- and Gβ1γ2-subunits, respectively. Although no basal interaction between the 
G-protein subunits and AC5 was observed, all subunits showed an increase in FRET 
upon agonist-stimulation of the according receptors. Interestingly, the different 
combinations of AC5 and G-protein subunits showed distinct FRET-signals. The 
agonist-dependent Gβ1γ2/AC5-FRET increase and decrease followed an exponential 
course, closely resembling other FRET-signals observed for G-proteins. FRET between 
Gαs and AC5 was characterised by a transient peak in the onset of the signal. 
Contrastingly, Gαi1 and AC5 showed an additional transient increase in their FRET-
signal upon agonist withdrawal. The signal-phenotypes observed between Gα-subunits 
and AC5 possibly indicate additional conformational changes within the G-protein/AC5 
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complex. The onset-kinetics of the interaction between AC5 and G-protein-subunits 
were fast and in the same range as previously observed G-protein activation-kinetics. 
The interaction between Gαi1 and AC5 was found to be especially sensitive and proved 
to be left-shifted in comparison to the activation of the Gi1-protein itself. Downstream 
events of Gi-dependent regulation of AC5 and Gi-protein activity further verified this 
difference on a functional level. Gi-dependent inhibition of AC5-regulated cAMP levels 
was determined with the newly established protocol for the FRET-based cAMP sensor 
Epac1-camps. In comparison to GIRK currents, which reflect Gi1-protein activity, the 
receptor-induced Gi-protein-mediated inhibition of stimulated AC5 activity was shifted 
by two orders of magnitude. This was in line with previous reports on higher sensitivity 
of cAMP-involving over Gi-protein activity-dependent pathways. After appropriate 
controls ruled out confounding mechanisms that could shift the apparent sensitivity of 
the assay, the interaction kinetics between AC5 and Gαi1 remained as a major 
contributing cause. Indeed the interaction of Gαi1-subunits with AC5 was prolonged in 
comparison to the deactivation of the Gi1-protein and could not be accelerated by 
RGS4. This indicates a slow dissociation of AC5 and Gαi1, which prevents the 
deactivation and reassembly of the Gi1-protein, thereby affecting the dynamics of the 
G-protein cycle. Presumably, the balance in the G-protein cycle between inactive and 
active G-proteins is shifted towards a higher amount of AC5-bound active G-proteins, 
providing the putative molecular mechanism for the high sensitivity observed in the 
interaction studies. 
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5 Zusammenfassung 
Praktisch alle Zellen des menschlichen Körpers verfügen über den Signalweg vom 
G-Protein-gekoppelten Rezeptor zum sog. „second messenger“ (zweiter Botenstoff) cAMP. 
Diese Signalkaskade ist von großer physiologischer und pathophysiologischer Bedeutung. 
Die in die Zellmembran eingelassenen Rezeptoren sind leicht zugänglich für 
pharmakologische Wirkstoffe. Daher beeinflussen verschiedene Krankheitstherapien, z.B. 
die Behandlungen von Bluthochdruck, Asthma und Schmerzen, direkt oder indirekt die 
zellulären cAMP-Spiegel. Biochemische Studien konnten bereits wichtige Informationen 
liefern über die Interaktion der an diesem Signalweg beteiligten Proteine. Dazu gehören die 
Rezeptoren selbst, die G-Proteine und die Adenylylzyklasen. Durch die Entwicklung 
neuartiger mikroskopischer Methoden konnten diese Interaktionen auch dynamisch 
untersucht werden. Derartige Techniken wurden bereits vielfach verwendet, um die 
Dynamik der Rezeptoraktivierung, des G-Proteins und des second messengers cAMP 
in vivo zu untersuchen. Die Erforschung der Adenylylzyklasen (AC) stützte sich bisher aber 
hauptsächlich auf in vitro Methoden oder Untersuchungen des Gleichgewichtszustandes der 
Interaktion der AC mit anderen Proteinen. 
Während dieser Arbeit wurde, basierend auf dem Förster Resonanzenergietransfer (FRET), 
eine neue Untersuchungsmethode entwickelt. Mit ihr ist es möglich, die dynamische 
Interaktion zwischen G-Proteinen und ACs zu erforschen und biochemische Studien in 
lebenden Zellen durchzuführen. Darüber hinaus wurde ein Protokoll für FRET-Messungen 
in lebenden Zellen etabliert, mit dessen Hilfe die Regulation von cAMP durch 
inhibitorische Gi-Proteine verfolgt werden kann. Um diese Versuche zu ermöglichen, 
wurde eine fluoreszenzmarkierte Typ V AC (AC5) kloniert. Dieses Konstrukt zeigte eine 
Wildtyp-ähnliche Funktionalität in Biolumineszenz-basierten cAMP-Untersuchungen, in 
denen Forskolin und stimulatorische G-Protein-Signalwege eingesetzt wurden. Mittels des 
neu entwickelten Protokolls für FRET-basierte cAMP-Untersuchungen konnte darüber 
hinaus nachgewiesen werden, dass die markierte AC5 auch durch Gi-Proteine reguliert 
wird. Auch hier unterschied sie sich nicht von unmarkierter AC5. 
Der neue Assay wurde verwendet, um die agonistabhängige Interaktion zwischen der AC5 
und den verschiedenen G-Proteinuntereinheiten (Gαs, Gαi und Gβ1γ2) zu untersuchen. Nach 
der Stimulation zugehöriger Rezeptoren wurde für alle Paarungen die Entwicklung eines 
FRET-Signals beobachtet, obwohl nicht festgestellt werden konnte, dass die Proteine unter 
nicht-stimulierten Bedingungen miteinander interagieren. Bemerkenswerterweise waren 
diese Signale für alle Paarungen unterschiedlich ausgeprägt. Der agonistabhängige Anstieg 
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im FRET zwischen Gβ1γ2-Untereinheiten und AC5 folgte einem monoexponentiellem 
Verlauf, ähnlich dem, der aus anderen G-Protein-Versuchen bekannt war. Der FRET-
Anstieg zwischen der Gαs-Untereinheit und AC5 war durch ein Maximum vor dem 
Signalplateau charakterisiert. Im Gegensatz zu diesen Kurvenverläufen zeigte das FRET-
Signal zwischen der Gαi1-Untereinheit und AC5 einen zusätzlichen vorübergehenden 
Anstieg, sobald der Agonist ausgewaschen wurde. Die verschiedenen Signalformen, die 
zwischen AC5 und den Gα-Untereinheiten beobachtet wurden, werden vermutlich durch 
zusätzliche Konformationsänderungen im G-Protein/AC-Komplex hervorgerufen. Für alle 
untersuchten G-Protein-Untereinheiten konnte festgestellt werden, dass sich die FRET-
Signale mit der AC5 schnell entwickelten und im gleichen zeitlichen Rahmen abliefen, wie 
die schon bekannte Aktivierung der G-Proteine an sich. 
Die Interaktion zwischen Gαi1-Untereinheit und AC5 stellte sich als besonders sensitiv 
heraus. Weitere Untersuchungen konnten belegen, dass die Empfindlichkeit dieser 
Wechselwirkung tatsächlich linksverschoben war gegenüber der Aktivierung des 
Gi1-Proteins an sich. Diese Verschiebung konnte durch die Untersuchung nachfolgender 
Signalschritte auch auf funktioneller Ebene bestätigt werden. Hierzu wurde die Gi-Protein-
abhängige Inhibierung der AC5 mittels des neu etablierten Protokolls zur FRET-basierten 
cAMP-Messung durch den Epac1-camps-Sensor gemessen. Im Vergleich zur Aktivität des 
GIRK-Kanals, der klassischerweise zur Bestimmung der Aktivität des Gi-Proteins 
verwendet wird, zeigte sich, dass die Rezeptor-abhängige, Gi-Protein-vermittelte 
Regulation der AC5 um zwei Zehnerpotenzen sensitiver war. Dieses Ergebnis bestätigt 
frühere Berichte, die ebenfalls eine deutlich höhere Sensitivität von cAMP-Signalwegen, im 
Vergleich zu Gi-Protein-Aktivitäts-basierten Signalen, gefunden hatten. Durch geeignete 
Kontrollen konnte ausgeschlossen werden, dass die Verschiebung der Sensitivität durch 
experimentelle Bedingungen hervorgerufen wurde. Somit blieb die Interaktionskinetik als 
wichtiger Einfluss übrig. Tatsächlich wurde entdeckt, dass die Interaktion der 
Gαi1-Untereinheit und AC5 länger andauerte, als durch die Deaktivierung des Gi1-Proteins 
zu vermuten war. RGS4 konnte diese lange Interaktion auch nicht signifikant verkürzen. 
Dieses Ergebnis deutet auf eine langsame Dissoziation von Gαi1 und AC5 hin, welche die 
Deaktivierung des Gi1-Proteins und nachfolgend die Formierung der inaktiven 
Konformation verzögert. Dadurch wird die Dynamik des G-Protein-Zyklus beeinflusst und 
vermutlich das Gleichgewicht zwischen inaktiven und aktiven G-Proteinen derart 
verschoben, dass mehr aktive, AC5-gebundene G-Proteine vorhanden sind. Dieser 
molekulare Mechanismus könnte die mutmaßliche Erklärung für die beobachtete hohe 
Sensitivität in den Interaktionsstudien liefern.  
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